A Comparison between Three Different Doses of Intrathecal Dexmedetomidine added to Hyperbaric Bupivacaine for Infra Umbilical Surgeries: A Study of 60 Cases by Premakumari, K
A COMPARISON BETWEEN THREE DIFFERENT DOSES OF 
INTRATHECAL DEXMEDETOMIDINE ADDED TO                              
HYPERBARIC BUPIVACAINE FOR INFRA 
UMBILICAL SURGERIES 
 
A STUDY OF 60 CASES 
DISSERTATION 
SUBMITTED   IN PARTIAL FULFILMENT OF UNIVERSITY 
REGULATIONS FOR THE AWARD OF 
M.D. DEGREE EXAMINATION 
 
 
 
 
 
BRANCH X -ANAESTHESIOLOGY 
 
THE TAMILNADU 
Dr. M.G.R. MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
MARCH -2013 
 
 CERTIFICATE 
This is to certify that this dissertation “A COMPARISON 
BETWEEN THREE DIFFERENT DOSES OF INTRATHECAL 
DEXMEDETOMIDINE ADDED TO HYPERBARIC 
BUPIVACAINE FOR INFRA UMBILICAL SURGERIES” presented 
herein byDr.K.PREMAKUMARI is an original work done in the 
Department of Anaesthesiology, Tirunelveli Medical College Hospital, 
Tirunelveli for the award of Degree of M.D (Branch - X) 
Anaesthesiology under my direct supervision and guidance, during the 
academic period of 2010 – 2013.  
 
 
 
DEAN 
Tirunelveli Medical College 
Tirunelveli-627007 
 
 
 
 
 CERTIFICATE 
This is to certify that the Dissertation “A Comparison 
Between Three Different Doses Of Intrathecal 
Dexmedetomidine Added To Hyperbaric Bupivacaine For 
Infra Umbilical Surgeries” presented herein by                      
Dr. K. PREMAKUMARI is an original work done in the 
Department of Anaesthesiology, Tirunelveli Medical College 
Hospital, Tirunelveli for the award of degree of M.D (BranchX) 
Anaesthesiology under my guidance and supervision during the 
period of 2010 - 2013. 
 
 
 
Professor and HOD, 
Dept. of Anaesthesiology, 
Tirunelveli Medical College and Hospital, 
Tirunelveli-627007. 
 
 
 DECLARATION 
I,Dr.K.PREMAKUMARI declare that the dissertation titled                        
“A comparison between three different doses of intrathecal 
dexmedetomidine added to hyper baric bupivacaine for infra 
umbilical surgeries” has been prepared by me. 
             This is submitted to the Tamil Nadu Dr. M.G.R. Medical 
University, Chennai, in partial fulfilment of the requirement for the award 
of M.D. degree, Branch X (ANAESTHESIOLOGY) Degree Examination 
to be held in April 2013. 
 
 
Place: Tirunelveli     DR.K.PREMAKUMARI 
Date:   
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT  
I wish to express my sincere thanks to                         
Prof. Dr.M.MANOHARAN, M.S., Dean, Tirunelveli Medical College, 
Tirunelveli for having kindly permitted me to utilize the hospital 
facilities. 
I wish to express my sincere thanks to 
Prof.Dr.N.PALANIAPPAN,MD.,Vice principal  Tirunelveli Medical 
College ,Tirunelveli  for his valuable help in carrying out this study. 
I am greatly indebted to Prof A.THAVAMANI M.D.., 
D.A,Professor and Head of the Department of Anaesthesiology, 
Tirunelveli Medical College, Tirunelveli for his guidance and 
encouragement during the period of this study, without which this 
dissertation would not have materialized. 
My heartfelt thanks to Prof. M. KANNAN M.D., D.A., Professor 
Emeritus, The TamilnaduDr. M.G.R Medical University, for his whole 
hearted help and support in doing this study. 
I have great pleasure in expressing my deep sense of gratitude to 
Prof. BALAKRISHNAN M.D., Professor of Anaesthesiology, 
Tirunelveli Medical College, Tirunelveli, for his constant support and 
guidance. 
I also thank the Associate Professors Dr. V. NALINI M.D., D.A, 
and Dr.K. SEVAGAMOORTHY M.D., D.A., fortheir constant support 
and guidance in performing this study.  
I am extremely thankful to Dr. G. VIJAY ANAND M.D., Senior 
Assistant Professor of Anaesthesiology, Tirunelveli Medical College, 
Tirunelveli for his sagacious advice and appropriate guidance to complete 
this study.                                                                
I also thank all the Assistant Professors, and Tutors for their able 
help, support and supervision during the course of the study. 
I thank all the Assistant Professors in the department of surgery 
and obstetrics and gynaecology for their able support, help and co-
operation during the course of the study. 
I extend my thanks to Mr. ARUMUGAM M. Sc, the statistician for 
his able analysis of the data. 
I thank all the patients included in the study and their relatives for 
their whole hearted co-operation in spite of their illness.  
Last but not the least I thank the God almighty who was with me 
during all these days. 
  
TABLE OF CONTENTS 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
TITLE 
INTRODUCTION 
AIM OF THE STUDY 
HISTORY OF PAIN 
PHYSIOLOGY OF PAIN  
ANATOMY OF SUBARACHNOID SPACE  
PHYSIOLOGY OF SUBARACHNOID BLOCK 
PHARMACOLOGY OF DRUGS  
REVIEW OF LITERATURE  
MATERIALS AND METHOD 
OBSERVATION AND RESULTS  
DISCUSSION 
SUMMARY  
CONCLUSION  
BIBLIOGRAPHY 
PROFORMA 
MASTER CHART 
Page No. 
1 
3 
4 
5 
10 
14 
24 
39 
47 
53 
76 
81 
82 
 
 
 
 
 
 1 
 
INTRODUCTION 
“It is the duty of the anesthesiologist to study the well-being o fthe patient as well as 
the convenience of the surgeon” 
-R.M.WATERS 
“It is not the drug that is dangerous, but the man who administers it is” 
- SIR ROBERT MACINTOSH 
The term ‘’spinal anesthesia’’was coined in 1885 by Leonard 
Corning, a neurologist. First planned spinal analgesia for surgery in man 
was performed by August Karl Gustav Bier on 16th August 1898 in Kiel 
and he was credited for introducing spinal anesthesia.Heinrich Quincke of 
Keil, Germany described the technique of lumbar puncture.  
Spinal anesthesia using local anesthesia is associated with 
relatively short duration of action and hence early analgesic intervention 
is needed in post operative period.A common problem during infra 
umbilical surgery under spinal anesthesia is visceral pain, nausea and 
vomiting. 
Adjuvants are added to improve the quality, to accelerate the onset 
of action and also to overcome the problems which occur during spinal 
analgesia.Adrenaline was the first spinal adjuvant used. Adrenaline 
reduces its toxicity but does not greatly prolong its effect. 
Various adjuvants like morphine, fentanyl, sufentanil, clonidine, 
midazolam, ketamine, neostigmine, sodabicarbonateare added to local 
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anesthetics and the latest inclusion is dexmedetomidine6. Adjuvants are 
administered by various routes like epidural, intrathecal and intravenous. 
In our study adjuvant is added to local anesthesic through intrathecal 
route.  
Alpha 2 adrenergic receptor agonist like dexmedetomidine gain the 
focus of interest for its sedative, analgesic, perioperative sympatholytic 
and hemodynamic stabilizing properties. Dexmedetomidine is a new 
highly selective drug among the alpha 2 adrenergic receptor agonist. It 
has been approved by FOOD AND DRUGS ADMINISTRATION for 
short term sedation for mechanically ventilated ICU patients. No 
neurological defects have been reported till date in both human and 
animal studies during intrathecal use. This study is intended to compare 
three different doses of intrathecal dexmedetomidine added to hyperbaric 
bupivacaine for infra umbilical surgeries (Unilateral Inguinal Hernia 
surgeries and Vaginal Hysterectomies) 
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AIM AND OBJECTIVES 
 To compare the effects of 3 different doses of intrathecal 
dexmedetomidine added to hyper baric bupivacaine for infraumbilical 
surgeries(Unilateral inguinal hernia and Vaginal Hysterectomies) with 
respect to  
1. Onset of sensory and motor blockade 
2. Duration of sensory and motor blockade 
3. Hemodynamic effects 
4. Duration of post operative analgesia 
5. Post operative sedation  
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HISTORY OF PAIN 
 Pain – It is derived from a Greek word ‘’poine’’ which means 
penalty.  CHARLES BELL and FRANCOIS MAGENDIE demonstrated 
that dorsal roots of the spinal cord transmit sensory information whereas 
ventral roots transmit motor information and the idea of specific neural 
pathway for painful sensations originated. 
Alpha 2 agonist have been used by veterinarians for many years for 
regional analgesia, but is being used in humans since 12 years. 
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PHYSIOLOGY OF PAIN 
 Pain is a complex phenomenon which includes sensory –
discriminative and motivational – affective components. The sensory 
component depends on ascending projection of tracts like spinothalamic 
and trigeminothalamic tracts into the cerebral cortex. They perceive 
quality of pain and help to know location of stimulus, intensity and 
duration of stimulus. 
Affective component includes attention, arousal, somatic, 
autonomic reflex, endocrine and emotional changes 
Pain receptors (Nociceptors): 
 Nociceptors are free nerve endings seen in the skin, muscles, 
viscera, joints and vasculature. Nociceptors detect the noxious stimulus 
due to the chemical, mechanical and thermal (heat & cold) changes. They 
can be classified into exteroceptors, which receive stimuli from skin 
surface and interoceptors that are located in the walls of viscera or deeper 
structures. These are free nerve terminals and are seen adjacent to small 
blood vessels and mast cells. Nociceptors operate as a functional unit 
with these. 
In addition to nociceptors, somatosensory receptors are located in 
the skin, which are sensitive to other forms of stimulation and each 
sensory unit includes an end-organ receptor, accompanying axon, dorsal 
root ganglion, and axon terminals in the spinal cord. 
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Inthe gate control theory of pain, Melzack and Wall (1965) 
proposed that inhibitory interneurons located in the superficial part of the 
dorsal horn played a crucial role in controlling incoming sensory 
information before it was transmitted to the brain through ascending 
pathways. 
The dorsal horn contains four major neuronal components: 
1. The central terminals of primary afferent axons 
2. Intrinsic neurons 
3. Projection neurons 
4. Descending axons that pass caudally from several brain regions. 
THE LAMINA OF REXED 
Rexed (1952) divided the dorsal horn of the cat spinal cord into a 
series of six parallel laminae, based on differences in the size and packing 
density of neurons (cyto architectonics). Lamina II can be subdividedinto 
two parts, referred to as lamina II inner (IIi) and lamina II outer (IIo). 
Laminae I and II are referred to as the superficial dorsal horn, constitute 
the main target for nociceptive primary afferents. The deeper laminae (III 
- VI) also have an important role in pain. Some nociceptive primary 
afferents terminate in this region, and many of the neurons in these 
laminae including some projection cells are activated by noxious 
stimulation. 
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Lamina I, also called as marginal layer, forms a thin two 
dimensional sheet covering the dorsal aspect of the dorsal horn and 
contains both projection neurons and inter neurons. 
A few large projection neurons are called as giant marginal cells of 
Waldeyer. Lamina II is also known as the substantia galatinosa, because 
the lack of myelinated fibres within it gives it a translucent appearance in 
unstained sections. Lamina III also contains a high density of neurons. 
Laminae IV - VI are more heterogeneous, with neurons of various sizes, 
some of which are projection cells. 
PRIMARY AFFERENT FIBRES: 
The somata of primary sensory neurons that innervate the limbs 
and trunk are located in sensory gangliaassociated with spinal nerves 
(dorsal root ganglia). Their axons bifurcate within the ganglion giving 
rise to peripheral and central branch, where it forms synapses with 
second-order neurons. Fibres innervating skin are described as cutaneous 
sensory neurons. 
Afferent fibres innervating abdominal or pelvic viscera are termed 
visceral afferents. 
Cutaneous sensory neurons: 
• Myelinated low-threshold mechanoreceptors 
• Myelinated nociceptive afferent fibres  
• Unmyelinated afferent fibres 
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Receptors associated with primary afferent neurons: 
Primary afferent fibres also possess a rich diversity of ligand-gated 
ionotropic, metabotropic and tyrosine kinase receptors which include 
both the alpha - amino - 3 - hydroxy - 5 - methyl - 4 - isoxazolepropionic 
acid (AMPA) and N - methyl - D - aspartate (NMDA) classes of 
ionotropic glutamate receptors and metabotropic glutamate receptors. 
Lastly, α2 adrenergic receptors are also found in sensory neurons and are 
thought to be localised at the central terminals of peptidergic fibres1 
PROJECTION NEURONS, SUBSTANCE P AND THE 
NEUROKININ 1 RECEPTOR: 
Neurons with axons that project to the brain are present in large 
numbers in lamina I and are scattered through the deeper part of the 
dorsal horn (laminae III - VI) and the ventral horn. 
Lamina I and some of the projection cells in deeper laminae, have 
axons that cross the midline and ascend to a variety of supra spinal targets 
including the thalamus, the midbrain periaqueductal grey matter, lateral 
para-brachial area of the pons and various parts of the medullary reticular 
formation. 
Substance P is present in many nociceptive primary afferents2 and 
there is evidence that this peptide and the neurokinin I (NKI) receptor, on 
which it acts, have a significant role in spinal pain mechanisms3. 
Substance P is released from primary afferents at extra synaptic 
sites and acts on NKI receptors on the projection neurons through volume 
transmission. 
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SPINAL INTERNEURONS: 
Interneurons make up the great majority of the neuronal population 
throughout the dorsal horn, laminae I - III contains a large number of 
interneurons since the packing density of neurons is particularly high. 
Classification of interneurons inhibitory and excitatory interneurons: 
Inhibitory interneurons can be subdivided into those that use 
GABA but not glycine as transmitters and that use both. 
Most excitatory interneurons are glutamatergic. 
GABA and glycine receptors: 
GABAA and glycine receptors are widely distributed in the spinal 
cord and are probably expressed by all dorsal horn neurons. 
DESCENDING MONOAMINERGIC AXONS: 
Serotoninergic axons in the spinal cord originate in the medullary 
raphe nuclei, while those that contain norepinephrine are derived from 
cells in the locus ceruleus and adjacent areas of the pons. 
Serotonin containing axons are widely distributed throughout the 
dorsal horn, but are numerous in laminae I and IIo. 
Norepinephrine containing axons can be identified with antibodies 
against appropriate synthetic enzymes (eg. dopamine - β hydroxylase). 
They are found throughout the dorsal horn, with high density in laminae I 
and II4. 
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ANATOMY OF SUB ARACHNOID SPACE 
The spine consists of 33 vertebrae (seven cervical, twelve thoracic, 
five lumbar,five fused sacral, four fused coccygeal).With the exception of 
C1 the cervical, thoracic and lumbar vertebrae consist of a body 
anteriorly, two pedicles that project posteriorly from the body and two 
laminae that connect the pedicles. These structures form the vertebral 
canal which contains a spinal cord, spinal nerves and epidural space. 
The laminae give rise to the transverse processes that project laterally and 
the spinous process that projects posteriorly. These bony projections 
serve as sites for muscle and ligament attachments. The pedicles contain a 
superior and inferior vertebral notch through which the spinal nerves exit 
the vertebral canal. 
The first cervical vertebrae differs from the typical structure in that 
it does not have a body or a spinous process. The five sacral vertebrae are 
fused together to form the wedge shaped sacrum which connects the 
spine with the iliac wings of the pelvis. The fifth sacral vertebrae is not 
fused posteriorly, giving rise to sacral hiatus. The sacral cornu are bony 
prominences on either side of the hiatus. The four rudimentary coccygeal 
vertebrae are fused together to form the coccyx. A line drawn between 
the iliac crests crosses the body of L5 or L4 -L5 interspace. 
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LIGAMENTS 
The vertebral bodies are stabilized by five ligaments that increase 
in size between the cervical and lumbar vertebrae. 
 Supraspinous ligament 
 Ligamentum nuchae 
 Ligamentum flavum 
 Anterior longitudinal ligament 
 Posterior longitudinal ligament 
Ligamentum flavum is a tough wedge shaped ligament composed 
of elastin. It consists of right and left portions that span adjacent vertebral 
laminae and fuse in midline to varying degrees. The ligamentum flavum 
is thickest in the midline, measuring 3-5 mm at the L2-3 interspace of 
adults. 
SPINAL MENINGES 
These spinal meninges consist of three protective membranes 
(duramater, arachnoid mater and piamater) which are continuous with the 
cranial meninges. 
Duramater 
The duramater is the outermost and the thickest meningeal tissue. 
The spinal duramater begins at the foramen magnum where it fuses with 
periosteum of the skull, forming the cephalad border of the epidural 
space. Caudally, the duramater ends at approximately S2 where it fuses 
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with the filumterminale. It is composed of collagen fibres and elastin 
fibres arranged longitudinally and circumferentially. The inner surface of 
the duramater abuts the arachnoid mater. There is a potential space 
between these two membranes called the subdural space. The incidence 
of subdural injection during intended subarachnoid injection may be as 
high as ten percentage as per radiological literature5. 
Arachnoid mater 
The arachnoid mater is a delicate, avascular membrane composed 
of overlapping layers of flattened cells with connective tissue fibers 
running between the cellular layers. The arachnoid mater herniates 
through the duramater into epidural space to form arachnoid granulations. 
The subarachnoid space lies between the arachnoid mater and piamater 
and contains the cerebro spinal fluid. Spinal cerebro spinal fluid is in 
continuity with the cranial cerebro spinal fluid and provides a venue for 
drugs in the cerebrospinal fluid to reach the brain. The spinal nerve roots 
and rootlets run in the subarachnoid space. 
Piamater 
The spinal piamater is adherent to the spinal cord and is composed 
of a thin layer of connective tissue cells interspersed with the collagen. 
The piamater extends to the tip of the spinal cord where it becomes the 
filumterminale which anchors the spinal cord to the sacrum.  
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SPINAL CORD 
 In the first trimester fetus,the spinal cord extends from the foramen 
magnum to the end of the spinal column.Thereafter the vertebral column 
lengthens more than the spinal cord so that at birth the spinalcord ends at 
about the level of the third lumbar vertebra.In the adult,the caudad tip of 
the spinalcord lies at the level of first lumbar vertebrae.The adult spinal 
cord measures approximately 41-48cm in length and weighs between 24-
36g,about 1 cm in diameter.The tapered end of the cord is called the 
conusmedullaris.The spinal cord gives rise to 31 pairs of spinal 
nerves,each composed of an anterior motor root and a posterior sensory 
root. 
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PHYSIOLOGY OF SUB ARACHNOID BLOCK 
The cerebrospinal fluid is an ultrafiltrate of the blood plasma, it is a 
colourless, clear fluid, present in spinal and cranial sub arachnoid space 
and in the ventricles of the brain. Average volume of CSF in adult is 120-
150 ml, among this 35 ml seen in the ventricles and 25 ml in the cerebral 
sub arachnoid space and 75 ml in the spinal sub arachnoid space. CSF is 
secreted by choroid plexus at a rate of about 0.3-0.4 ml/minute. 
PHYSICAL CHARACTERISTICS OF CSF 
The pH is 7.4. The specific gravity is 1.007 and density is 1.0003, 
baricity is 1.000and the CSF pressure varies between 8-12 mm Hg, cell 
count is 3-5/ cumm and the protein content is 20 mg/dl and glucose 
content varies between 40-80mg /dl. 
The CSF mainly plays a role in spinal anesthesia and it serves as a 
media for dispersionof the local anaesthetic drug in the spinal nerve  
Spread of the drug in sub arachnoid space is determined by the specific 
gravity of the injected drug when compared with that of CSF.  
MECHANISM OF SPINAL ANESTHESIA 
The nerves of the sub arachnoid space do not have the protection of 
dura or arachnoid, therefore even a small amount of local anaesthetic in 
the CSF will cause a profound block of nerve transmission. 
Local aesthetics for spinal anesthesia is usually injected into the 
sub arachnoid space between the spinous processes of the third and fourth 
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lumbar vertebra, the needle will enter the Dura in the area of the 
caudaequina, the place where the nerve roots cross the sub arachnoid 
space from the spinal cord to the point of exit through the dura. Surface 
area of nerve roots is considerable, thus making them vulnerable to the 
effects of local anaesthetic. Local anaesthetics penetrate the smaller roots 
more rapidly because of the largest surface area7. Spinal cord also takes 
up local anaesthetic mainly by diffusion through piamater. But the 
concentrations of local anaesthetics are higher in nerve roots than in the 
cord because of easy accessibility of local anaesthetic. Local anaesthetics 
cause sodium channel blockade within the dorsal and ventral horns, thus 
inhibits the generation and propagation of electrical activity 
The block and recovery of sensory fibres occurs in this order: The 
most sensitive sensory fibres-C fibres (sensation to cold)-are blocked first 
and remain blocked longest; A delta fibres (pin-prick)are the second to be 
blocked and recover; A β fibres(touch)are the last to  block and first to 
recover. 
The preganglionic sympathetic fibres (B –fibres) are most sensitive 
to local anaesthetics. The motor fibres (Aα, the largest fibers) are less 
sensitive to local anaesthetics comparing to sensoryfibers and there is a 
difference between sensory and motor block, motor function is better 
preserved since more local anaesthetic is needed to anesthetize the thick 
motorfibers. 
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UPTAKE AND ELIMINATION OF LOCAL ANESTHETICS 
FROM CEREBROSPINAL FLUID  
Factors affecting uptake of local anaesthetic (LA) into neural tissue: 
¾ Concentration of LA in cerebrospinal fluid(CSF) 
¾ Surface area of tissue exposed to CSF 
¾ Lipid content of nerve 
¾ Blood flow of nerve 
Elimination of LA from CSF: 
¾ Through the arachnoidea and dura to epidural space  
¾ Vascular absorption via sub arachnoid and epidural blood 
vessels 
Spread of Local Anaesthetics in Sub arachnoid Space 
The main factor influencingthe spread of drug in the CSF is the 
relationship between density of the local Anaesthetic in relation to the 
density of the CSF at a specific temperature called baricity.  Density of a 
solution is the weight in grams /ml of a solution(g/ml)at a specified 
temperature. Anaesthetic substance that have a greater density than CSF 
are called hyperbaric and those with the lower density are called 
hypobaric and local anaesthetic with density close to the CSF are called 
isobaric  and factors like gender and hormonal status in 
women(menopause, pregnancy)affect on CSF density.  With hyperbaric 
solutions the spread is more influenced by baricity and the duration of 
 17 
 
block also increases when the dose is increased when hyperbaric 
solutions are used8,9. Hypobaric and hyperbaric solutionsare prepared by 
adding distilled water and dextrose to isobaric solution respectively. 
Gravity does not influence the spread of isobaric solution and hence 
height of block is not influenced by changing the position of the patient. 
Hyperbaric solutions settle to the most dependent aspect of the sub 
arachnoid space and since it is heavier than CSF in supine position, 
hyperbaric solution spread to the level of thoracic kyphosis and hypobaric 
solution floats up. 
INDICATION 
Infra Umbilical surgeries, lower limb surgeries and urological 
surgeries, obstetric and gynaecological surgeries and surgeries around the 
perineum. Spinal anesthesia can be combined with epidural anesthesia for 
anesthesia in obstetrics, vascular and orthopaedic surgeries. 
CONTRAINDICATIONS 
Absolute Contraindications 
• Patients refusal despite adequate information.  
• Infections at the site of injection 
• Dermatologic conditions 
• Septicemia or Bacteremia 
• Shock or severe hypovolemia 
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• Abnormality in blood clotting mechanism 
• Increased intracranial pressure 
• Lack of skill in spinal anesthesia 
• Allergy to local anesthesia 
Relative contraindications 
¾ Deformities of the spinal column 
¾ Pre-existing disease of the spinal cord 
¾ Chronic head ache or back ache 
¾ Inability to achieve a spinal tap in three attempts 
¾ Cardiac diseases – marked aortic stenosis 
SPINAL ANESTHESIA TECHNIQUE 
PREPARATION AND MONITORING OF THE PATIENT 
Proper patient selection is mandatory for successful procedure, 
which includes thorough pre anesthesic evaluation Wide bore IV line, 
blood pressure and heart rate monitor, pulseoximeter, equipment for 
airway management, working suction apparatus, two oxygen cylinder and 
emergency drugs(atropine, ephedrine) kept ready in the syringes.  
POSITION OF THE PATIENT  
Lateral decubitus position is the most popular position because of 
comfort. The patient should be placed with the back parallel to the edge 
of the table closest to the anesthesiologist. The vertebral column is then 
flexed to widen the interlaminar spaces, by drawing the knees upto the 
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chest and putting the chin down on the chest, the head supported by a 
pillow. 
Sitting position is used for obstetrical, certain gynaecologic, and 
urologic procedures. This position facilitates identification of the midline 
particularly in obese patients in whom there will be difficulty 
NEEDLES FOR SPINAL ANESTHESIA: 
Needles either of small bore or with a rounded, non-cutting bevel 
are used.  
The Quincke-Babcock spinal needle (needle with sharp point with 
a medium length cutting bevel), the Whitacre needle and the Sprotte 
needle (needles of completely rounded, non cutting bevels with solid tips, 
openings are on the side, 2 to 4 mm proximal to the tip) are used. 
Quincke type: 
Opening at the tip causing injectate to flow in a straight direction. 
Sprotte type: 
As hole in the side, the flow is directed approximately 45 degrees 
from the longitudinal axis. 
ASEPTIC TECHNIQUE  
Before the spinal anesthesia, the anesthesiologist must perform a 
thorough surgical scrub using alcohol-based antiseptic solutions.  
The patient’s back is prepared with alcohol based antiseptic solution and 
sterile drapes are applied. The insertion site for lumbar puncture should 
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be identified by the line between the upper border of the iliac crests, 
which passes through either the spinous process of L4 or the interspace 
between L4 and L5. Spinal needle is introduced through Midline 
approach either in sitting /right lateral decubitus position.26 gauge spinal 
needle is used and the needle is introduced  through middle of the 
interspace and after piercing the skin and subcutaneous tissue , it is 
advanced in a cephalad direction with the long axis of the vertebral 
column. Stylet is gently removed, appearance of CSF through the hub of 
the needle confirms correct position of needle, and the stylet is again 
inserted to prevent leakage of CSF.The hub of the needle is held between 
thumb and index finger of the anesthesiologists non dominant hand and 
syringe is attached to the needle, gentle aspiration done to confirm free 
flow of spinal fluid and the drug is injected. Then the patient is placed in 
supine position continuous monitoring of vital parameters done and level 
of analgesia confirmed byloss of sensation to pinprick.  Motor block was 
assessed by modified Bromage score. 
PHYSIOLOGIC RESPONSES 
A: EFFECTS ON CARDIOVASCULAR SYSTEM10 
The responses are due to combined effects of autonomic 
denervation, with higher levels of blockade, the added effects of vagal 
nerve innervation. Spinal anesthesia causes some degree of hypotension 
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and reflex bradycardia because of reduction in cardiac output and 
systemic vascular resistance. 
The level of sympathetic denervation determines the magnitude of 
cardio vascular responses to spinal anesthesia, the higher the level of 
neural blockade, the greater the change in cardio circulatory parameters. 
Sympathetic denervation produces arterial and arteriolar vasodilation 
which is not maximal, whereas veins and venulesvasodilate maximally 
due to loss of vascular smooth muscle tone. 
The bradycardia seen during spinal anesthesia is due to blockade of 
preganglionic cardiac accelerator fibres arising from T1 to T4 during high 
levels of anesthesia11. 
The bradycardia is also mediated by significant decreases in right 
atrial pressure and pressure in the great veins as they enter the right 
atrium. The direct relationship between right atrial pressure and heart rate 
during high spinal anesthesia is mediated by intrinsic chronotropic stretch 
receptors located in the right atrium and adjacent great veins, the 
mechanism for these changes is described as Bezold-Jarisch reflex.  
EFFECTS ON RESPIRATORY SYSTEM 
High spinal anesthesia cause intercostal paralysis, Arterial blood 
gas tension, resting tidal volume, maximum insipiratory volume, remain 
unaltered because diaphragmatic activity is unimpaired. Maximum 
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breathing capacity and maximum expiratory volume are diminished. 
Phrenic nerves are unaltered.  
Gastro Intestinal Effect: 
Preganglionic fibres from T5-L1 are inhibitory to gut. So in 
sympathetic blockade the small intestine contracts with relaxed sphincters 
and peristalsis remains normal. Handling of viscera causes discomfort 
and bradycardia since vagus is not blocked. 
Hepatic and Renal Effects: 
The hepatic blood flow decreases and is directly proportional to 
thedecrease in blood pressure. There may be normal hepatic 
oxygenextraction. Renal blood flow is maintained by autoregulation and 
does not decrease till mean arterial pressure goes below 50mmHg. 
Genito Urinary System: 
Sphincters of bladder are not relaxed, and the ureteric tone are not 
greatly altered. Urinary retention occurs. Penis is often engorged. Uterine 
tone is unchanged in pregnancy. In the absence of hypotension spinal 
anesthesia has got no effect on the progress of labour and uterine blood 
flow. 
Metabolic and hormonal effect: 
Spinal anesthesia blocks the hormonal and metabolic responses to 
nociceptive stimuli arising from the operative site. It minimizes the rise in 
blood sugar, cortisol, catecholamines, renin and aldosterone release 
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associated with stress. Post operative negative nitrogen balance and 
secretion of antidiuretic hormone are inhibited 
THERMO REGULATION 
Extensive spinal blockade impairs central thermo regulatory 
control12. The main cause of hypothermia during spinal anesthesia is the 
redistribution of blood flow and heat to the periphery because of 
vasodilation.  
COMPLICATIONS OF SUB ARACHNOID BLOCK 
Immediate  
¾ Hypotension 
¾ Bradycardia 
¾ Toxicity due to intravascular injection 
¾ Allergy to local anaesthetic drug. 
¾ Hypotension(brainstem hypoxia) 
Late 
¾ Post dural puncture headache 
¾ Retention of urine 
¾ Backache 
¾ Meningitis  
¾ Transient lesions of caudaequina 
¾ Sixth nerve palsy 
¾ Anterior spinal artery syndrome  
hydr
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lignocine. It is more cardiotoxic than lignocaine and which is aggravated 
by hypoxia, hypercapnia and by pregnancy. It causes more sensory than 
motor block .It is not recommended for intravenous regional analgesia. 
Duration of effect is between 5 and 16 hours and is one of the longest 
acting local analgesics, which is related to binding to nerve tissue. Small 
percentage of a given dose of drug is excreted unchanged in the urine and 
the remainder is metabolised in the liver.  
Uses: 
• Spinal anesthesia 
• Epidural anesthesia 
• Caudal anesthesia 
• Continuous epidural anesthesia 
• Peripheral nerve block 
• Infiltration anesthesia 
Onset time and duration of action 
Site of action Onset (minutes) Duration (minutes) 
Intrathecal 5 90-120 
Epidural 15-20 165-225 
Brachial plexus 10-20 600 
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Pharmacokinetics: 
Once injected intrathecally, it gets absorbed by the nerve rootlets 
and it is rapidly absorbed from the site of injection, but the rate of 
absorption depends on the vascularity and the presence of 
vasoconstrictors. 
Because of high lipid solubility it easily penetrates nerve and 
vascular tissue. 80-95% of absorbed bupivacaine binds to the plasma 
proteins. 
Distribution: 
Rapid distribution phase: (α)  
Slow disappearance phase: (β) 
Biotransformation: 
Possible pathways of metabolism of bupivacaine include aromatic 
hydroxylation and conjugation. Only the N-dealkylated metabolite, N-
desbutyl bupivacaine has been measured in blood (or) urine after epidural 
(or) spinal anesthesia. Alpha1 acid glycoprotein is the most important 
plasma protein binding site of bupivacaine and its concentration is 
increased by many clinical situations including post operative trauma. 
Excretion: 
It is through the kidney, 4-10% of the drug is excreted unchanged. 
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Mode of Action: 
a) Site of action: 
i) The spinal nerve rootlet fine nerve filaments having a large surfacearea 
are exposed to the local anaesthetics. 
ii) Posterior and lateral aspects of the spinal cord. 
b) Sodium Channel blockade: 
They impede sodium ion access to the axon interior by occluding 
the transmembrane sodium channels thus delaying the process of 
depolarization and axon remains polarized. It is a non-
depolarisationblockade. 
Pharmacodynamics: 
It has got a longer duration of action but a slower onset. 
Cardiovascular system: 
It reduces cardiac output by reducing the sympathetic tone, by 
slowing the heart rate and by reducing the venous return, it produces a 
fall in arterial blood pressure but it is relatively slow and is seldom very 
profound. It produces a fall in central venous pressure. It causes an 
increase in lower limb blood flow. It causes a reduction in incidence of 
deep vein thrombosis. 
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Respiratory System: 
It relaxes bronchial smooth muscle. It causes apnea due to phrenic 
and intercostal nerve paralysis or depression of the medullary respiratory 
center following direct exposure to drug. 
Gastro intestinal tract: 
There is an increase in gastro intestinal motility and emptying of 
the gastric contents are better. 
Toxicity: 
Toxicity is related to plasma level of unbound drug and more likely 
due to an inadvertant intravenous injection. Systemic toxicity reactions 
primarily involve central nervous system and cardio vascular system. The 
blood level required to produce central nervous system toxicity is less 
than that required to produce circulatory collapse. 
Central Nervous System Toxicity: 
Early symptoms are circumoral numbness, tongue paresthesia and 
dizziness. Sensory complaints include tinnitus and blurred vision. 
Excitatory signs (restlessness, agitation, nervousness, paranoia) often 
precede central nervous system depression (slurred speech, drowsiness, 
unconsciousness). Muscle twitching heralds the onset of tonic clonic 
seizures. Respiratory arrest often follows. The excitatoryreactions are the 
result of selective blockade of inhibitory pathways. 
 
Card
fibre
bupi
high
atrio
arrhy
card
1999
is u
adren
It is
Atip
seda
iovascula
The rate
s and ven
vacaine in
 concentra
ventricula
thmias su
iac arrest. 
PHA
Dexmed
. It is used
sed less 
oceptor a
 shorter-a
amezole f
tive and a
r System
 of depol
tricular m
duced blo
tion of th
r heart blo
ch as ven
RMACO
etomidine
 as a short
than 24 
gonist. It 
cting dru
or its seda
nalgesic, 
 Toxicity:
arization 
uscle is 
ck is slow
e drug ca
ck, idiove
tricular ta
LOGY O
 is an∝2- a
-term seda
hrs. Dex
is used in 
g than cl
tive effect
as premed
29
 
in fast co
decreased
er than t
uses sinu
ntricular r
chycardia
F DEXM
gonist tha
tive analg
medetomi
high dose
onidine. a
. It is use
ication, a
nducting 
. The rat
hat of lign
s bradyca
hythms, a
, ventricul
EDETOM
t received
esic espec
dine is a
s for sedat
nd it has
d in perio
s an anes
tissue of 
e of reco
ocaine.Ex
rdia, hypo
nd life thr
ar fibrilla
IDINE 
 FDA app
ially in the
 selectiv
ion and an
 a revers
perative p
thesic adj
 
purkinje 
very of 
tremely 
tension, 
eatening 
tion and 
roval in 
 ICU. It 
e ∝2 – 
algesic. 
al drug 
eriod as 
unct for 
 30 
 
general  as well as regional anesthesia and also for post operative sedative 
and analgesic14. 
Physiology of ∝2  -adrenoceptors. 
Alpha 2 – adrenoceptors are found in peripheral and central 
nervous systems, also  in  effector organs like   liver, kidney, 
pancreas,eye, vascular smooth muscles and platelets. 
They are divided into 3 subtypes. ∝2  A- predominant subtypes in 
CNS, this is responsible for the sedative, analgesic and sympatholytic 
effect. 
Dexmedetomidine is 8 to 10 times more selective towards ∝2 AR 
than Clonidine. ∝2 B –found mainly in the peripheral vasculature, and is 
responsible for the short term hypertensive response. 
∝2 C-found in the CNS, Which is responsible for the 
anxiolyticeffect15. 
All these subtypes produce cellular action by signalling through a 
G-Protein which couples to effector mechanisms, and the coupling differs 
depending on receptor sub-type and location. The ∝2 A-Subtype appears 
to couple in an inhibitory fashion to the calcium channel in the locus 
ceruleus of the brain stem and in the vasculature, the ∝2 B subtype couple 
in an excitatory manner to the same effector mechanism. 
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Mechanism of action of dexmedetomidine: 
Dexmedetomidine possess unique properties and it differs from 
other sedative drugs. ∝2 – adrenoceptors are found in many sites 
throughout the CNS, but the highest densities are found in the locus 
ceruleus, the predominant noradrenergic nuclei of the brainstem which is 
an important modulator of vigilance. Presynaptic activation of ∝2 
Aadrenoceptor in the locus ceruleus inhibits nor epinephrine (NE) release 
and results in sedative and hypnotic effects. Locus ceruleus is the site of 
origin for descending medullospinal noradrenergic pathway which is an 
important modulator of nociceptive neuro transmission. Stimulation of 
the ∝2 –adrenoceptors in this area terminates mainly the propagation of 
pain signals leading to analgesia. Post synaptic activation of ∝2 – 
adrenoceptors in the CNS causes decrease in sympathetic activity which 
leads to hypotension and bradycardia. Also cardiac vagal activity is 
augmented and all the effects together produce analgesia, sedation and 
anxiolysis. 
At the spinal cord, stimulation of ∝2 –receptors at the substantia 
gelatinosa causes inhibition of the firing of nociceptive neurons and 
inhibition of release of substance P.∝2adrenoceptors also have analgesic 
mechanisms by preventing NE release at the nerve endings whereas  the 
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spinal mechanism is the principal mechanism for the analgesic action, but 
clear evidence exists for both supraspinal and peripheral sites of action16.  
∝2 - receptors located on blood vessels mediates vasoconstriction whereas 
those located on sympathetic terminals  inhibit NE release. In other areas 
these ∝2 adrenoceptors cause contraction of vascular and other smooth 
muscles, decreased salivation, decreased secretion and decreased bowel 
motility in the gastrointestinal tract, and also it causes inhibition of renin 
release, increased glomerularfiltration, increased sodium and water in the 
kidney, decreased insulin release from pancreas, decreased intraocular 
pressure, decreased platelet aggregation and decreased shivering 
threshold by 2oC17. 
Pharmacokinetics: Absorption and distribution: 
Dexmedetomidine in the dose range of 0.2 to 0.7 µg/kg /hr exhibits 
linear pharmacokinetics and it is administered as intravenous infusion 
upto 24 hours. Also the distribution phase is rapid, its half life of 
distribution is approximately 6 minutes, and eliminationhalf life is 2 
hours. 
The steady-state volume of distribution is 118L Average protein 
binding is 94%. Context- sensitive half life ranges from 4 minutes after a 
10-minute infusion to 250 minutes after an 8-hour infusion. Its oral 
bioavailability is poor, which is because of extensive first-pass 
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metabolism. The bioavailability of sublingual route is high (84%) and it 
offers a potential role in pediatric sedation and premedication18. 
Metabolism and excretion 
Dexmedetomidine undergoes biotransformation through direct N- 
glucuronidation and cytochrome P-450 (CYP 2A6) mediated aliphatic 
hydroxylation to its inactive metabolites. Metabolites are excreted in the 
urine(95%) and in the feces (4%). Dose has to be reduced in patients with 
hepatic failure. 
Pharmacodynamics of Dexmedetomidine 
∝- adrenoceptor agonists have different ∝2 / ∝1 selectivity.∝2 / ∝1 
selectivity of dexmedetomidine is 1620:1 whereas it is low for clonidine 
and hence dexmedetomidine is 8 times more powerful ∝2 – adrenoceptor 
than clonidine. 
CVS: 
Dexmedetomidine does not have any direct effects on the heart. It 
causes a dose dependent increase in coronary vascular resistance and 
oxygen extraction and the supply / demand ratio is unaltered. It evokes a 
biphasic blood pressureresponse. A short hypertensive phase and 
subsequent hypotension and the 2 phases are mediated by 2 different ∝2 –
AR Subtypes: the ∝-2B AR is responsible for the initial hypertensive 
phase, hypotension is mediated by the ∝2A –AR19.  Younger patients 
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with high level of vagal tone develop bradycardia and sinus arrest which 
were effectively treated with anticholinergic agent. 
RS: 
Dexmedetomidine does not produce respiratory depression even at 
high doses. It can be safety used in spontaneously breathing ICU patients 
after surgery. It maintains sedation without cardiovascular instability or 
respiratory drive depression. Hence it is used during weaning and 
extubation in trauma / surgical ICU Patients in whom previous attempts 
at weaning have failed because of agitation associated with hyperdynamic 
cardio pulmonary response20. 
CNS: 
Dexmedetomidine reduces cerebral blood flow and cerebral 
metabolic requirement of oxygen. Dexmedetomidine enhances 
cumulative performance and also possess sedative, analgesic and 
anxiolytic action through ∝2 –AR21 .It reduces levels of circulating  and 
brain cetecholamines, thus balancing the ratio between cerebral oxygen 
supplies and reduces excitotoxicity, improves the perfusion in the 
ischemic penumbra, hence it possess excellent neuroprotective action. In 
subarachnoid haemorrhage it reduces the levels of glutamate which in 
responsible for cellular brain injury. 
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Endocrine and renal effects 
 Dexmedetomidine activates peripheral presynaptic ∝2–AR, thus 
catecholamine release is reduced and hence sympathetic response to 
surgery is also reduced. It is an imidazole agent but doesnot inhibit 
steroidogenesiswhen used as an infusion for shortterm sedation22. 
Adverse Effects: 
Side effects reported are hypotension, hypertension, nausea, 
vomiting, dry mouth, bradycardia, atrial fibrillation, pyrexia, chills, 
pleural effusion, atelectasis, pulmonary edema, hyperglycemia, 
hypocalcaemia, acidosis, etc., Transient hypertension  is produced when 
dexmedetomidine infusion is rapidly administered (Loading dose of 
1µg/Kg / hr if given less than 10 minutes) and this is mediated by 
peripheral ∝2B –AR vasoconstriction.  
The occurrence of Hypotension and bradycardia is mediated by 
central ∝2A-AR, causing decrease of noradrenaline release from the 
sympathetic nervous system. Supersensitization and up regulation of 
receptors occur during long term use, hence abrupt discontinuation not 
advised. Withdrawal syndrome of nervousness, agitation, headache and 
hypertensive crisis occur during abrupt discontinuation.                               
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Clinical applications of dexmedetomidine premedication 
Dexmedetomidine is used as an adjuvant for premedication since 
this drug possess sedative, anxiolytic, analgesic, sympatholytic, and 
stable humodynamic profile. Premedication dose is 0.33 to 0.67 mg /kg 
IV given 15 minutes before surgery. Oxygen consumption is decreased in 
intraoperative period and in post operative period23.  
Intra operative use: 
Dexmedetomidine attenuates the homodynamic stress response 
which occurs during intubations and extubation by sympatholysis24. 
Dexmedetomidine potentiates anaesthetic effect of all the anaesthetic 
agents, thus reducing their requirement.  
Loco regional analgesia 
Highly lipophilic nature of dexmedetomidine facilitates rapid 
absorption into the cerebrospinal fluid. It binds to ∝2 – AR of spinal cord 
for its analgesic action. Sensory and motor block produced by local 
anesthetics is prolonged. It is also used in intravenous regional anesthesia 
(IVRA), brachial plexus block and intraarticularly. It is also given 
through intraarticular route in arthroscopic knee surgeries to improve the 
duration of postoperative analgesia.  
Sedation in ICU 
Dexmedetomidine produce cooperative sedation. It does not 
interfere with the respiratory drive hence it facilitates early weaning from 
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ventilator, thus reducing ICU stay costs. Many studies have 
recommended their use for longer than 24 hrs25. Their other beneficial 
effects are analgesic sparing effects, reduced delirium and agitation, 
minimal respiratory depression and desirable cardio vascular effects. 
Procedural sedation  
Dexmedetomidine is used for short term procedural sedation like 
transesophageal echocardiography, colonoscopy, awake carotid 
endarterectomy, shockwave lithotripsy, elective awake fiberoptic 
intubation26,pediatric MRI. The dose is 1 µg/kg which is followed by an 
infusion of 0.2µg/kg/h. 
Controlled hypotension 
Spinal fusion surgery for idiopathic scoliosis, septoplasty and 
tympanoplastyoperations and maxillofacial surgery have been done with 
dexmedetomidine induced hypotension. 
Analgesia 
Dexmedetomidine activates ∝2 –AR in the spinal cord, thus the 
transmission of nociceptive signals is reduced. It possesses significant 
opioid sparing effect. 
Cardiac surgery 
Dexmedetomidine reduces the extent of myocardial ischemia 
during cardiac surgery. Its other uses are in the management of 
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pulmonary hypertension in patients undergoing mitral valve 
replacement27. 
Neurosurgery 
Dexmedetomidine possess neuro protective effect. It also 
attenuates delirium and agitation, so that postoperative neurological 
evaluation will be easier. It has a role in functional neurosurgery like 
awake craniotomy surgeries and implantation of deep brain stimulators 
for Parkinson’s disease28. 
Obesity: 
In morbidly obese patients this drug does not cause respiratory 
depression in the dose of 0.7µg /kg intra operatively.  
Obstetrics 
Dexmedetomidine is also used in obstetrics due to its maternal 
hemodynamic stabilizing property. It also produces anxiolysis and 
stimulation of uterine contractions. Since it is highly lipophilic it does not 
cross placenta and hence it cause less chance of fetal bradycardia. 
Pediatrics 
Recently it is used in pediatric patients for sedation during non-
invasive procedures in radiology like CT scan and MRI 29. 
Other uses 
Used as an anti-shivering agent Used in the treatment of 
withdrawal from benzodiazepines, opioids and alcohol. 
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REVIEW OF LITERATURE 
1. SubhiM Al-Ghanam et al(2009)30 studied the effect of adding 
Dexmedetomidine versus fentanyl to intrathecal 0.5% isobaric 
bupivacaine on spinal characteristics in gynecological procedures. 
This  double blind prospective study was conducted in 78 patients and 
half of them received Dexmedetomidine 5µg and the remaining half 
received 25µg fentanyl with 10mg isobaric Bupivacaine.It was found 
that the mean time of sensory regression to S1 and also the regression 
of motor block was significantly longer in Dexmedetomidine 
group.Hence it was concluded that when comparing to 25µg of 
fentanyl,5µg of Dexmedetomidine seems to be an attractive alternative 
as an adjuvant to spinal bupivacaine with only a very minimal 
sideeffects and excellent quality of spinal analgesia in gynecological  
procedures. 
2. Rajni Gupta et al(2011) 31studied the effect of adding 
Dexmedetomidine with isobaric Ropivacaine for post operative 
analgesia.This randomized double blind study was conducted in sixty 
patients divided into two groups and one group received 3 ml of 
0.75% isobaric Ropivacaine with 0.5 ml normal saline,other group 
received 3 ml of 0.75% isobaric Ropivacaine with 0.5 ml of 
Dexmedetomidine5µg. Their study showed that mean time of 
regression to S1 and the duration of analgesia was significantly 
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prolonged in Dexmedetomidine group. It was concluded that the 
addition of Dexmedetomidine to Ropivacaine intrathecally produces a 
prolongation in the duration of motor as well as sensory block.   
3. Rajni Gupta et al (2011)32 studied the comparative effect of intrathecal 
Dexmedetomidine and fentanyl as adjuvants to bupivacaine.They have 
found that intrathecal Dexmedetomidine is  associated  with prolonged 
motor and sensory block, hemodynamic stability and reduced need for 
rescue analgesia in 24 hrs as compared to fentanyl. 
4. Mahmoud M Al-Mustafa et al(2009)33studied the effect of different 
doses of Dexmedetomidine when added to spinal isobaric bupivacaine 
for urological procedures.This study was conducted in 66 patients who 
were randomly assigned into three groups.The first group received 
Bupivacaine 12.5 mg with saline, the second group received 12.5 mg 
Bupivacaine with 5µg of Dexmedetomidine, and the third group 
received 12.5mg Bupivacaine with 10µg of Dexmedetomidine.Itwas 
observed that the onset of sensory and motor block was significantly 
faster and duration of sensory and motor block was significantly 
prolonged in Dexmedetomidine group in a dose dependent 
manner.Hence it was concluded that Dexmedetomidine has a dose 
dependent effect on the onset and regression of sensory and motor 
block when it is added as adjuvant to Bupivacaine in spinal anesthesia. 
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5. Hala E A Eid et al(2011)34studied the dose related effect of intrathecal 
Dexmedetomidine when added to hyperbaric Bupivacaine .This 
double blind prospective randomized study was conducted in forty 
eight patients who were scheduled for anterior cruciate ligament 
reconstruction.First group received 10µg of Dexmedetomidine, the 
second group received 15µg ofdexmedetomidine and third group 
received normal saline with 3ml of 0.5% bupivacaine.It wasfound that 
the two segment regression, sensory regression to S1,regression of 
motor block to modified bromage 0,time to first rescue analgesia was 
prolonged significantly with Dexmedetomidine.Also it was associated 
with decreased post-operative pain score.Hence it was concluded that 
intrathecal Dexmedetomidine in doses of 10µg and 15µg causes 
prolongation of anaesthetic and analgesic effects of spinal hyperbaric 
bupivacaine in a dose dependent manner. 
6. Ashraf Amin Mohamed et al35 studied the comparison of analgesic 
efficacy of intrathecally administered Dexmedetomidine or 
Dexmedetomidine combined with fentanyl in patients undergoing 
major abdominal cancer surgery. This double blind randomized study 
was conducted in ninety patients  who received intrathecally 10 mg  
bupivacaine 0.5%(control group)or 10mg bupivacaine0.5% and 5µg 
Dexmedetomidine (Dexmedetomidine group)or 10mg bupivacaine 
0.5%and 5µg Dexmedetomidine and 25µg fentanyl 
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(Dexmedetomidine plus group).It was concluded that  
Dexmedetomidine  5µg when given intrathecally improves the quality 
and the duration of postoperative analgesia and also it provides an 
analgesic sparing effect in  patients undergoing major abdominal 
cancer surgery and it was proved that fentanyl has no valuable clinical 
effect. 
7. KANAZI et al studied36,the effect of low dose Dexmedetomidine or 
clonidine on the characteristics of bupivacaine spinal block.This 
randomized prospective double blind study was conducted in sixty 
patients undergoing transurethral resection of prostate or bladder 
tumour under spinal anesthesia. The patients were randomly allocated 
into one of three groups. Group B received 12mg of hyperbaric 
bupivacaine,group D received 12mg of bupivacaine supplemented 
with 3µg of Dexmedetomidine and group C received 12mg of 
bupivacaine supplemented with 30µg of clonidine. It was concluded 
that when Dexmedetomidine 3µg or clonidine 30µg when added to 
intrathecal bupivacaine causes a similar prolongation in duration of 
the sensory and motor blockade with   preserved hemodynamic 
stability and lack of sedation. 
8. DeepikaShuklaet al37 conducted a comparative study of intrathecal 
dexmedetomidine with intrathecal magnesium sulphate when used as 
adjuvants to bupivacaine. This prospective randomized double-blind 
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study was conducted in 90 patients to evaluate the onset and duration 
of sensory and motor block and also the peri operative analgesia and 
adverse effects of Dexmedetomidine and magnesium sulphate when 
given intrathecally with 0.5% hyperbaric bupivacaine for spinal 
anesthesia. It was concluded that onset of anesthesia was rapid and of 
prolonged duration in the Dexmedetomidine group when compared to 
magnesium sulphate group and the groups were similar with respect to 
hemodynamic variables and there were no side effects in either of 
them. 
9. Anand et al 38studied the effects of caudal Dexmedetomidine 
combined with ropivacaine to provide post-operative analgesia in 
children and also established its safety in pediatric population. This 
double blind, randomized, prospective, parallel group study was 
conducted in 60 children who were allocated into two groups. Group 
RD received 0.25% ropivacaine 1ml/kg with Dexmedetomidine 
2µg/kg making the volume to 0.5 mg and Group R received 0.25% 
ropivacaine 1ml/kg + 0.5 ml normal saline.Induction done with 50% 
N2O and 8% sevoflurane in oxygen with spontaneous ventilation. It 
was concluded that caudal Dexmedetomidine (2µg/kg) with 0.25% 
ropivacaine (1 ml/kg) for pediatric lower abdominal surgeries result in 
significant post-operative pain relief and better quality of sleep and a 
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prolonged duration of arousable sedation with less incidence of 
emergence agitation. 
10. Ibrahim F A Khalifa39 conducted a study in fifty ASA grade I&II 
patients, who were scheduled for elective inguinal hernia repair. 25 
patients in Group D received Dexmedetomidine 0.5 ml and group S 
patients received sufentanil 0.1 ml + normal saline 0.4 ml added to 2 
ml heavy bupivacaine. They concluded that the addition of 
Dexmedetomidine 5µg and sufentanil 5µg intrathecally provide 
improved post operative analgesia and better hemodynamic stability. 
Also it was found that 5µg Dexmedetomidine seems to be an attractive 
alternative as adjuvant to spinal bupivacaine in prolonged surgical 
procedures with minimal side effects and excellent quality of spinal 
analgesia. 
11. A E Kyles et al40 studied that intrathecal administration of the α2-
adrenoceptor agonists, clonidine, xylazine, guanfacine and 
Dexmedetomidine produced dose dependant antinociception in the rat. 
These studies also demonstrate that a significant proportion of the 
antinociceptive effect of systemically administered xylazine is 
mediated by spinal α2-adrenoceptors. 
12. AnjuGrewal et al41 reported the experimental animal and human 
studies of intrathecal Dexmedetomidine added as an additive to local 
anesthetics, and found that there is a dose dependent prolongation of 
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sensory block, increase in motor block, along with prolongation of the 
post operative analgesia, thus reducing the dose requirement in high 
risk group of patients. 
13. Lawhead R G  et al42 suggested that the predominant α2-adrenergic 
sub type present in human spinal cord is the α-2A sub type and the α2 
–adrenergic receptor density was found to be significantly greater in 
the sacral region of the cord as compared to lumbar or thoracic 
regions. 
14. L Hennawyet al43 studied that the addition of clonidine or 
Dexmedetomidine to bupivacaine prolongs caudal analgesia in 
children. 
15. Tatsushiet al44 have concluded that all α2- adrenoceptor agonists 
enhance the degree of local anesthesia of lidocaine in a dose-
dependent manner and suggested that Dexmedetomidine acts through 
α-2A adrenoceptors. 
16. Eisenach,Dekock et al45 have studied  that  when  clonidine is 
administered intrathecally  with bupivacaine  it cause prolongation of 
sensory and motor block. 
17. KritonS.Filos, et al46 evaluated the dose-response hemodynamic and 
analgesic profiles of intrathecal clonidine after a surgical 
intervention,without perioperative administration of other 
analgesics.This study was done in 3 groups of patients who received 
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150,300,450µg clonidine and postoperative analgesia was assessed.It 
was found intrathecal clonidine decreases pain in all 3 groups in a 
dose dependent manner with hemodynamic stability. 
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MATERIALS AND METHODS 
Study design: 
This was a randomised, prospective, parallel group, double-blinded 
study. 
Randomisation: 
Simple randomised sampling was done by computer generated 
random numbers. 
Sample size: 
Sixty patients were studied. 
INCLUSION CRITERIA: 
• Age between 18-60 years of both sexes 
• ASA I and II patients 
• Elective surgeries (Inguinal herniorrhaphy and Vaginal 
hysterectomies) 
EXCLUSION CRITERIA: 
• Known hypersensitivity to any of study drugs 
• Known contra indication to Regional Anesthesia 
• Known or suspected coagulopathy 
• Renal disorders 
• Hypertension , IHD , Heart blocks ,Arrhythmias, Cardiac valvular 
abnormalities 
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• Patients on β blockers 
• Patient on any long term analgesic therapy 
• Patient on medications known to interact with study drugs 
Allocation: 
After obtaining Institutional Research and Ethical Committee 
(TIREC) approval and written informedconsent, the patients were 
randomlyallocated into three groups. 
1. Group A (n=20) 
2. Group B (n=20) 
3. Group C (n=20) 
Intervention: 
Spinal administration of the drug mixture 
1. Group A (n=20) – 0.5% hyperbaric bupivacaine 2.4ml (12mg) + 
dexmedetomidine 5 µg in 0.6 ml normal saline. 
2. Group B (n=20) – 0.5% hyperbaric bupivacaine 2.4ml (12mg) + 
dexmedetomidine 10 µg in 0.6 ml normal saline. 
3. Group C (n=20) – 0.5% hyperbaric bupivacaine 2.4ml (12mg) + 
dexmedetomidine 15 µg in 0.6 ml normal saline. 
Masking: 
The anesthesiologist who administered the drug and theobserver 
were blinded to the study. Sterile syringescontaining 3.0 ml of the total 
volume of the drug wereloaded by another anesthesiologist not 
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participating in the study. The intraoperativemonitoring and postoperative 
observation was doneby the same anesthesiologist who administered 
thedrug, but was unaware of the content of thesyringes. 
Pre-anesthetic evaluation: 
Patients included in the study underwent thorough pre-operative 
evaluation which included the following. 
HISTORY 
History of co-morbid medical illness, any previous history of 
surgery under anesthesia evaluated.  
PHYSICAL EXAMINATION 
¾ General condition of the patient  
¾ Vital signs 
¾ Examination of CVS,RS,CNS and spinal columns 
¾ Airway assessment          
¾ Investigations like Hb%, BT, CT, Random blood sugar, BloodUrea, 
SerumCreatinine, Chest X ray, ECG, Bloodgrouping&typing done 
Emergency drugs and equipmentswere kept ready. Pre-loading 
done with 20 ml/kg of intravenous infusion of Ringer lactate. Monitors 
were connected to the patients and baseline values of heart 
rate,systolic,diastolic,mean arterial pressure,oxygen saturation were 
noted. 
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Under strict aseptic precaution the sub-arachnoid block was done 
approaching through L3-L4 interspacewith a 26 gauge quincke’s needle. 
After confirming free flow of CSF, the drug was injected according to the 
group assigned.  After injecting the drug, the patients were turned to 
supine position. When the peak level of sensory block is reached, the 
surgeon was instructed to proceed. 
The following parameters were recorded:   
Pulse rate, systolic blood pressure, mean blood pressure, diastolic 
blood pressure, respiratory rate, SPO2 were recorded before starting 
procedure and thereafter 5, 10, 15, 20,  mins interval till  the end of the 
surgery and thereafter at hourly second and fourth hourly interval till 24 
hours. Hypotension was defined as systolic blood pressure less than 
90mm Hg or decrease in MAP below 20%of the baseline value. 
Hypotension, if any occurred was treated with Inj.Ephedrine(6mg) 
incremental boluses. 
SENSORY BLOCKADE: 
Sensory blockade was assessed by pin prick with a short 
hypodermic needle at 1 minute interval until the block reached T10 level 
and the maximum height of the sensory block was noted at 20 
minutes.Onset of sensory blockade was defined as the time taken from 
the drug injection to the time to reach T10 level and the offset of sensory 
block was presumed when pin prick sensation at S1 dermatome has 
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returned.Duration of sensory block was defined as the time interval 
elapsed between onset of sensory block at T10 to regression of sensory 
block to S1. 
MOTOR BLOCKADE: 
Assessed using Modified Bromage score. 
 GRADE     
0 - No motor block 
 1 - Inability to raise extended legs 
 2 - Inability to flex knee joints 
 3 - Inability to flex ankle joints 
This was assessed at 1 minute interval until complete motor block 
occurred. Onset of motor block was defined as the time taken from the 
injection of drug to the development of complete motor blockade, i.e., 
Bromage score-3. Complete recovery from motor block was defined as 
attaining Bromage score-0 and the duration of motor block means that the 
time taken from the onset of complete motor blockade to complete 
recovery of motor block. 
ASSESSMENT OF PAIN: 
Pain was evaluated using Visual Analogue Scale. 
0-1 Excellent 
2-4  Good 
5-6  Fair 
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7-8  Poor 
9-10   No relief 
Inj. Diclofenac 75mg was administered intra-muscularly as a 
rescue analgesic when the pain score crossed a score of 4. 
Duration of Analgesia: 
It is the period from the time of subarachnoid block to the time 
when the patient needs the first dose of rescue analgesic drug. 
SEDATION: 
Assessed using Ramsay Sedation Score. 
Grade Description 
1 Anxious and agitated 
2 Cooperative and tranquil 
3 Drowsy but responsive to command 
4 Asleep but responsive to a glabellar tap 
5 Asleep with a sluggish response to tactile 
stimulation 
6 Asleep and no response 
Post operatively the patients were followed for upto 24 hrs for any 
adverse effectslike nausea, vomiting, pruritus,respiratory depression,any 
neurological complications and urinary retention. 
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OBSERVATION AND RESULTS 
Statistical Analysis: 
The statistical procedures were performed by the statistical package 
IBM SPSS statistics - 20. The P - values less than 0.05 (P<0.05) were 
treated as significant in two tail condition.  The Randomization of three 
groups was done by matching their ages, demographic factors and 
hemodynamic factors such as pulse rate, SBP, MAP SPO2, and duration 
of surgeryby ANOVA (Analysis of Variance). The differences between 
them were interpreted by the Post hoc test of Bonferroni. Similarly, the 
onset time for sensory block, and motor blocks were compared between 
groups by ANOVA. The intra and post-operative pulse rates, SBP, MAP 
and SPO2 at different intervals were compared between groups by 
ANOVA and interpreted the difference by Post hoc test of Bonferroni. 
The sensory level and sedation score between three groups were analyzed 
and interpreted by χ2 test (Chi- square). The duration of analgesia between 
the groups were analyzed and interpreted by Kaplan- Mayer Survival 
Function.  
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RESULTS: 
Randomization by group matching: 
Table-1.Matching of three groups according to their age. 
Variables Group n Mean S D 
ANOVA
’F’ 
df Significance
Age 
A 20 44.4 10.7
 
0.249 2, 57
 
P>0.05 
B 20 46.0 5.6    
C 20 44.4 8.1    
  
The three groups were matched according to their age for 
randomization and found that there was no difference between the mean 
ages between them (44.4 ± 10.7 ≈46.0±5.6 ≈ 44.4±8.1 and P>0.05). 
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Table-2. 
Matching of three groups according to their preoperative 
hemodynamic Characteristics and duration of surgery. 
Variables Group n Mean S D 
ANOVA 
’F’ 
df Significance 
Pre Pulse 
rate 
A 20 82.2 4.4  
2.015 
 
2, 57 
 
.143 
 
B 20 85.7 7.3 
C 20 82.4 6.6 
Pre SBP 
A 20 120.5 10.9  
1.610 
 
2, 57 
 
.209 
 
B 20 119.9 10.1 
C 20 125.4 10.7 
Pre MAP 
A 20 91.1 6.9 
0.620 2, 57 
 
.541 
 
B 20 89.8 8.1 
C 20 92.6 9.1 
Pre SPO2 
 
A 20 99.8 0.4  
2.375 
 
2, 57 .102 B 20 99.8 0.4 
C 20 100.0 0.0 
DOS A 20 97.6 34.1  
0.620 
 
2, 57 .542 B 20 100.9 30.3 
C 20 108.1 26.1 
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Table – 2 shows the haemodynamic variables and the duration of 
surgery of three groups. The mean pre-op pulse rate, SBP, MAP, SPO2 
and duration of surgery were matched and found that no significant 
differences were observed between the three groups (P>0.05).  
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TABLE - 3 
Comparison of onset of blockade between groups. 
Block Groups N Mean 
(Sec.) 
SD ANOVA 
‘F’ 
df Sig (P) 
OTSB 
A 20 226.1 28.7 
8.903 
 
2, 57 
 
.000 
 B 20 206.8 14.9 
C 20 197.2 20.2 
OTMB 
A 20 233.0 23.3 
31.733 
 
 
2, 57 
 
.000 B 20 228.2 16.8 
C 20 190.4 14.2 
  
Table – 3 shows the comparison of onset of sensory and motor 
blockade between the three groups. The mean on set time of A group was 
significantly higher than the other two groups B&C (A>B&C; 
226.1±28.7>206.8±20.2&197.2±14.9 and P<0.05).  The mean values of 
B& C groups were approximately equal (206.8±20.2≈197.2±14.9 and 
P>0.05). 
The mean onset time of motor blockade of C group was 
significantly lower than the other two groups (190.4±14.2< 233.0±23.3 & 
228.2±16.8 and P<.001). The onset time for motor block of the other two 
groups namely A and B were not significant (233.0±23.3 ≈ 228.2±16.8 
and P>0.05). 
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The level of sensory blockade is compared between the three 
groups in Table 4.The highest sensory level achieved for A group was T6 
and C group was T4.Among the A&B group subjects, 65% and 40% were 
associated with T8 sensory level and among the C group subjects 40% 
were associated with T4 sensory level. The above levels were statistically 
very highly significant (P<0.001). 
 
Comparison of PR, SBP, MAP, & SPO2 at different time between 
groups: 
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Table-5.Comparison of Pulse Rate between groups at different 
time interval. 
Pulse rate Group n Mean S D F Df Sig  (P) 
5 Minutes 
A 20 79.9 3.7  
0.481 
 
2, 57 
 
.621 
 
B 20 81.8 6.4 
C 20 80.3 8.3 
 
10 Minutes 
A 20 78.3 3.2  
1.619 
 
2, 57 
 
.207 
 
B 20 82.3 7.6 
C 20 78.5 10.8 
 
15 Minutes 
A 20 76.6 3.4  
2.872 
 
2, 57 
 
.065 
 
B 20 83.9 11.7 
C 20 78.0 12.7 
30 Minutes 
A 20 78.1 4.5  
1.345 
 
2, 57 
 
.269 
 
B 20 81.2 9.8 
C 20 76.5 11.9 
1 Hour 
A 20 75.8 4.2  
1.477 
 
2, 57 
 
.237 
 
B 20 80.7 9.9 
C 20 77.1 12.0 
 2 Hours 
A 20 75.6 4.1  
2.825 
 
2, 57 
 
.068 
 
B 20 81.7 8.3 
C 20 76.9 11.4 
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 3 Hours 
 
A 20 75.7 4.1  
2.428 
 
2, 57 
 
.097 
 
B 20 81.4 6.8 
C 20 77.9 11.8 
 8 Hours 
A 20 76.5 6.1  
1.368 
 
2, 57 
 
.263 
 
B 20 81.2 8.7 
C 20 78.3 11.4 
12 Hours 
A 20 77.3 5.7  
1.472 
 
2, 57 
 
.238 
 
B 20 81.8 8.6 
C 20 79.2 10.2 
 18 Hours 
A 20 79.1 5.0  
0.640 
 
2, 57 
 
.531 
 
B 20 82.0 8.6 
C 20 79.6 11.1 
 24 Hours 
A 20 79.7 6.2  
0.342 
 
2, 57 
 
.712 
 
B 20 82.0 8.7 
C 20 80.6 10.9 
  
The Pulse rates at different intervals such as at 5,10,15,30 minutes, 
1, 2, 3,8,12, 18 and 24 hours are shown in the above Table-5. The mean 
pulse rates at the above different times between the three groups are not 
significantly different (P>0.05). 
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Comparison of  Pulse Rate between groups at different time interval 
  
TABLE-6. 
Comparison of SBP between groups at different time interval. 
SBP Group n Mean S D F df Sig  (P) 
5 Minutes 
A 20 111.5 10.3  
1.723 
 
2, 57 
 
.188 
 
B 20 110.4 9.4 
C 20 118.7 22.5 
 
10 Minutes 
A 20 107.0 9.2  
2.842 
 
2, 57 
 
.067 
 
B 20 106.5 7.4 
C 20 113.8 14.5 
 
15 Minutes 
A 20 102.0 9.5  
1.515 
 
2, 57 
 
.228 
 
B 20 102.5 8.5 
C 20 107.8 15.6 
30 Minutes 
A 20 104.0 9.9  
3.044 
 
2, 57 
 
.055 
 
B 20 104.8 9.3 
C 20 113.1 17.7 
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1 Hour 
A 20 107.1 15.4  
0.073 
 
2, 57 
 
.930 
 
B 20 108.3 15.1 
C 20 108.8 12.7 
 2 Hours 
A 20 111.3 14.8  
0.157 
 
2, 57 
 
.855 
 
B 20 112.3 14.1 
C 20 109.9 11.6 
 3 Hours 
 
A 20 111.3 14.8  
0.046 
 
2, 57 
 
.955 
 
B 20 112.5 14.4 
C 20 112.6 16.1 
 8 Hours 
A 20 107.5 7.8  
0.084 
 
2, 57 
 
.919 
 
B 20 108.5 8.1 
C 20 107.8 7.7 
12 Hours 
A 20 109.1 9.5  
0.199 
 
2, 57 
 
.820 
 
B 20 109.7 9.7 
C 20 108.0 6.1 
 18 Hours 
A 20 109.1 9.5  
0.233 
 
2, 57 
 
.793 
 
B 20 109.8 9.7 
C 20 111.0 7.1 
 24 Hours 
A 20 108.8 9.6  
0.597 
 
2, 57 
 
.554 
 
B 20 109.5 10.5 
C 20 112.0 8.9 
  
The SBP at different intervals such as at 5,10,15,30 minutes, 1, 2, 
3,8,12, 18 and 24 hours are shown in the above Table-6. The mean SBP 
at the above different times between the three groups are not significantly 
different (P>0.05). 
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Comparison of SBP between groups at different time interval. 
 
Table-7. Comparison of MAP between groups at different time 
interval. 
MAP Group n Mean S D F df Sig  (P) 
5 Minutes 
A 20 87.4 6.3  
1.001 
 
2, 57 
 
.374 
 
B 20 86.0 7.3 
C 20 89.9 11.8 
 
10 Minutes 
A 20 82.6 7.5  
0.817 
 
2, 57 
 
.447 
 
B 20 81.5 7.1 
C 20 85.4 13.5 
 
15 Minutes 
A 20 80.7 7.8  
0.091 
 
2, 57 
 
.913 
 
B 20 80.0 8.3 
C 20 81.2 11.3 
30 Minutes 
A 20 81.1 7.7  
0.388 
 
2, 57 
 
.680 
 
B 20 81.9 7.7 
C 20 83.5 10.5 
1 Hour A 20 81.2 10.3  2, 57  
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B 20 82.5 10.3 0.113 
 
.893 
 C 20 81.3 7.3 
 2 Hours 
A 20 84.3 8.6  
0.063 
 
2, 57 
 
.939 
 
B 20 84.5 8.5 
C 20 85.3 10.8 
 3 Hours 
 
A 20 86.0 8.7  
0.054 
 
2, 57 
 
.948 
 
B 20 87.0 7.9 
C 20 86.5 10.6 
 8 Hours 
A 20 84.9 7.8  
0.180 
 
2, 57 
 
.836 
 
B 20 85.9 7.5 
C 20 84.3 9.3 
12 Hours 
A 20 85.5 8.5  
0.987 
 
2, 57 
 
.379 
 
B 20 86.2 8.3 
C 20 82.9 6.5 
 18 Hours 
A 20 85.0 8.0  
0.549 
 
2, 57 
 
.581 
 
B 20 85.9 7.7 
C 20 83.4 7.1 
 24 Hours 
A 20 85.7 8.0  
0.386 
 
2, 57 
 
.681 
 
B 20 86.7 7.7 
C 20 84.6 6.7 
  
The MAP at different intervals such as at 5,10,15,30 minutes, 1, 2, 
3,8,12, 18 and 24 hours are shown in the above Table-7. The mean MAP 
at the above different times between the three groups are not significantly 
different (P>0.05). 
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Table-8. Comparison of SPO2 between groups at different time 
interval. 
SPO2 Group n Mean S D F df Sig  (P) 
5 Minutes 
A 20 99.5 0.5  
1.354 
 
2, 57 
 
.266 
 
B 20 99.4 0.6 
C 20 99.2 0.5 
 
10 Minutes 
A 20 98.8 0.5  
2.146 
 
2, 57 
 
.126 
 
B 20 99.0 0.6 
C 20 99.2 0.5 
 
15 Minutes 
A 20 98.9 0.6  
2.678 
 
2, 57 
 
.077 
 
B 20 99.0 0.6 
C 20 99.3 0.4 
30 Minutes 
A 20 99.6 0.5  
1.004 
 
2, 57 
 
.373 
 
B 20 99.8 0.3 
C 20 99.8 0.4 
1 Hour 
A 20 99.8 0.4  
0.377 
2, 57 
 
.687 B 20 99.9 0.3 
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C 20 99.8 0.3   
 2 Hours 
A 20 99.8 0.3  
0.138 
 
2, 57 
 
.872 
 
B 20 99.9 0.3 
C 20 99.8 0.3 
 3 Hours 
 
A 20 99.9 0.2  
1.000 
 
2, 57 
 
.374 
 
B 20 100.0 0.0 
C 20 100.0 0.0 
 8 Hours 
A 20 100.0 0.0  
1.000 
 
2, 57 
 
.374 
 
B 20 99.9 0.2 
C 20 100.0 0.0 
12 Hours 
A 20 99.9 0.2  
1.000 
 
2, 57 
 
.374 
 
B 20 100.0 0.0 
C 20 100.0 0.0 
 18 Hours 
A 20 99.9 0.2  
0.500 
 
2, 57 
 
.609 
 
B 20 99.9 0.2 
C 20 100.0 0.0 
 24 Hours 
A 20 99.90 0.2  
1.000 
 
2, 57 
 
.374 
 
B 20 100.0 0.0 
C 20 100.0 0.0 
  
The SPO2 at different intervals such as at 5,10,15,30 minutes, 1, 2, 
3,8,12, 18 and 24 hours are shown in the above Table-8. The mean SPO2 
at the above different times between the three groups are not significantly 
different (P>0.05). 
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Comparison of SPO2 between groups at different time interval 
 
TABLE – 9.Comparison of duration of Sensory and Motor blocks 
between groups. 
Block Groups N 
Mean
(min.)
SD 
ANOV
A ‘F’ 
df Sig (P) 
DSB 
A 20 241.0 48.9 19.37
1 
 
2, 57 
 
.000 
 
B 20 290.0 56.2 
C 20 341.5 47.6 
DMB 
A 20 260.6 41.5 52.83
9 
 
 
2, 57 
 
.000 B 20 318.0 31.0 
C 20 362.5 16.5 
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The Duration of Sensory block and Motor blocks are shown in the 
above Table -9.  The duration of sensory block of C group was 
significantly longer than B and B group was significantly longer than A 
group (341.5±47.6>290±56.2>241.0 ±48.9 and P<0.001).  
Similarly the duration of motor block of C group was significantly 
longer than B and B group was significantly longer than A group 
(362.5±16.5>318.0 ±31.0>260.6±41.5 and P<0.001).  
Comparison of duration of Sensory and Motor blocks between 
groups 
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TABLE - 10 
Comparison of 2 segment regression time between three groups 
Groups N Mean SD 
ANOVA 
‘F’ 
df 
Sig 
(P) 
A 20 139.7 28.2 
7.760 
 
2, 57 
 
 
.001 B 20 143.2 28.8 
C 20 172.7 30.2 
  
The 2 segment regression time between the three groups is shown 
in the above table 11. The two segment regression times between three 
groups were 139.7±28.2, 143.2±28.8 and 172.7±30.2.minutes 
respectively. The group C regression time was significantly greater than 
the other two groups (172.7±30.2.> 143.2±28.8 &139.7±28.2, and 
P<0.00). But the regression times between the groups A and B was not 
significant (143.2±28.8 ≈139.7±28.2 and P<0.05). 
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Fig.-1. Comparison of Analgesia survival functions between three 
groups. (Kaplan Meier Survival function curve) 
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The Fig-1 explains the time of analgesia from the starting of 
anesthesia to the onset of VAS pain score 4. The range of group A was 
250 to 480 minutes, B group was 440 to 500 and C group was 600 to 840 
minutes.  
TABLE - 12 
Comparison of Sedation Score between three groups. 
Sedation score A B C Total χ2 Df Sig 
2 20 15 0 35 
 
47.946 
 
 
4 
 
.000 
3 0 5 11 16 
4 0 0 9 9 
Total 20 20 20 60 
  
The Sedation Score of three groups are compared in Table-12. The 
highest sedation score achieved for A group was 2 and C group was 4. 
The C group achieved more sedation levels wherein 55% reached score 3 
and 45% reached score 4. The above levels were statistically very highly 
significant (P<0.001). 
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Adverse effects: 
  The adverse effects are enumerated between three groups and 
associated with the respective groups. 
Table-13.The adverse effects between the groups. 
Adverse 
effects 
Group,1=A,2=B,3=C 
Total χ2 Df Sig 
1 2 3 
 
Nausea & 
Vomiting 
0 0 0 0 
1.780 
 
.776 
 Pruritus 0 0 0 0 
 
Respiratory 
depression 
0 0 0 0 
 
Urinary 
retention 
0 0 0 0 
0
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Brady cardia 1 1 2 4 
Hypotension 1 2 3 6 
Total 2 3 5 10 
  
The above table-13 associates the adverse effects between the three 
groups. Bradycardia and Hypotension were the only adverse effects 
noted, and was much associated with the C group. But the association 
within the groups did not have any statistical significance (P>0.05). 
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DISCUSSION 
Recent researches have revealed that the administration of an α2-
agonist in the centro-neuraxial blockade produces prolonged 
postoperative pain relief without undue sedation. This effect is due to the 
sparing of supraspinal CNS sites from excessive drug exposure, resulting 
in analgesia without heavy sedation. The mechanism by which intrathecal 
α2-adrenergic agonists prolong the motor and sensory block of local 
anesthetics is still not clearly understood. Intrathecal α2-adrenergic 
agonists produce analgesia by depressing the release of C-fiber 
transmitters and by hyperpolarization of post-synaptic dorsal horn 
neurons. This anti-nociceptive effect may explain the prolongation of the 
sensory block when added to spinal anaesthetics. The prolongation of the 
motor block of spinal anaesthetics may result from the binding of α2-
adrenergic agonists to motor neurons in the dorsal horn. 
Most of the clinical experience gained in the use of intrathecal α2- 
adrenoceptor agonists has been described with clonidine, which has a 
potent synergistic effect with local anaesthetics. There are only few 
research available using a combination of intrathecal dexmedetomidine 
and local anaesthetics. The dose of epidural/ caudal dexmedetomidine 
reported is in the range of 1.5 - 2 µg/kg.38 Compared with clonidine, 
dexmedetomidine has 10 times higher receptor binding affinity. 
Extrapolations led to the calculation of an equipotent dose of intra-
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thecally administered dexmedetomidine. Several clinical studies have 
established that intrathecal clonidine increases the duration of sensory 
and motor spinal block when added to spinal local anaesthetics and this 
effect of clonidine is dose-dependent.45 Doses of more than 75 μg are 
accompanied by excessive sedation, hypotension and bradycardia. 
Intrathecal dexmedetomidine upto 10µg added to local anaesthetics has 
not produced any major adverse effects during the studies conducted by 
these authors discussed above. De kocket al45 recommended a dose of 15-
45 μg clonidine for supplementation of spinal anesthesia which 
effectively prolongs the duration of spinal block with minimal sedation 
and side effects. Higher intrathecal doses of clonidine have been tried. 
But there is no published literature for intrathecal doses of more than 
10µg of dexmedetomidine. The equipotent dose for 5, 10 and 15µg of 
dexmedetomidine when compared to clonidine would approximate 50, 
100 and 150µg respectively. 
Kanazi et al,36 who pioneered using dexmedetomidine in humans 
for spinal anesthesia, hypothesized that intrathecal  dexmedetomidine 3 
µg or clonidine 30 µg would be equipotent and would produce a similar 
effect on the characteristics of bupivacaine spinal anesthesia. These 
conclusions were arrived, pondering over previous animal studies using 
intrathecal dexmedetomidine. The authors added a low dose of 3 µg of 
dexmedetomidine or 30 µg of clonidine to 12 mg of intrathecal 
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bupivacaine. They found no significant difference between the groups 
with respect to blockade characteristics, analgesia and sedation. They 
confirmed their hypothesis that the intrathecal doses of dexmedetomidine 
and clonidine used in the study are equipotent. Al-Mustafa et al,33 
hypothesized that 5 µg and 10 µg of intrathecal dexmedetomidine might 
be equipotent to 50 µg and 100 µg of intrathecal clonidine respectively. 
They administered dexmedetomidine intrathecally along with 
bupivacaine to a maximum dose of 10µg. They observed that 
dexmedetomidine had a dose dependant effect on the onset and regression 
of sensory and motor block when used as an adjuvant to bupivacaine in 
spinal anesthesia. Ashraf Amin Mohamed et al,35 compared 5µg 
dexmedetomidine with 25µg fentanyl added to bupivacaine for 
abdominal surgeries. They observed that intrathecal 5 μg 
dexmedetomidine improved the quality and the duration of postoperative 
analgesia. In another similar study, Subhi Al-Ghanemet al30compared the 
effect of adding 5µg dexmedetomidine versus 25µg fentanyl to 
intrathecal bupivacaine in vaginal hysterectomies. They concluded that 
10 mg plain bupivacaine supplemented with 5 μgdexmetedomidine 
produces prolonged motor and sensory block compared with 25 μg 
fentanyl. Gupta et al,31 from their study, concluded that 5µg 
dexmedetomidine added to ropivacaine intrathecally produces a 
prolongation in the duration of the motor and sensory block. Shukla et 
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al,37 compared 10µg of intrathecal dexmedetomidine to magnesium 
sulphate as adjuvants to bupivacaine, and concluded that 
dexmedetomidine provided earlier onset and prolonged duration of 
sensory and motor blockade, without any significant hemodynamic 
alterations.  
In the present study, we observed that the onset time of sensory and 
motor blockade was dose dependent (table - 3). Group A (226.1±28.7 
seconds) significantly differed (P<0.001) with group B (197.2±14.9 
seconds) & C (206.8±20.2 seconds) in respect of their sensory on set 
time. This means that the onset of sensory blockade was earlier with 
higher doses. The onset time of motor block was also earlier with 
increasing doses. Group C (190.4±14.2 seconds) significantly differed 
(P<0.001) with group A (233.0±23.3 seconds) & group B (228.2±16.8 
seconds). A dose related increase in the level of sensory blockade 
(C>B>A) was noted (table - 4). The duration of sensory and motor blocks 
(table - 9) between the groups was also dose dependent, and significantly 
(P<0.001) differed from each other. The duration of both sensory and 
motor blockade was highest with group C (sensory mean-341.5±47.6 
minutes, motor mean-362.5±16.5 minutes). The 2 segment regression 
time (table – 10) was highest with group C (mean-172.7±30.2 mins). The 
mean duration of analgesia was dose dependent (table – 11, figure - 1) 
with C>B>A (740.5 ±65.9>471.0±24.6> 347.5± 101.4 minutes; 
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P<0.001). The post-operative sedation (table – 12) was also dose 
dependent with group C exhibiting a minimum score of 3 and maximum 
of score 4. None of the patient showed signs of respiratory depression. 
From the present study, it is clear that intrathecal dexmedetomidine 
with spinal bupivacaine not only shortens the onset of anesthesia, but also 
prolongs the duration of blockade and achieves longer duration of 
analgesia. Adverse effects pertained to opioid administration, such as 
nausea, vomiting, pruritus and urinary retention were not noted in any of 
the patient (table – 13). Bradycardia and hypotension occurred in 10 out 
of 60 patients, with group C>B>A (5, 3 and 2 respectively), but were not 
statistically significant. Bradycardia required no treatment, and correction 
of hypotension required less than 12-18 mg of ephedrine in incremental 
boluses. Otherwise the patients remained hemodynamically throughout. 
The statistical analysis of the pre, intra and post-op hemodynamic 
variables such as PR, SBP, MAP and SPO2 between the three groups 
showed no statistically significant hemodynamic fluctuation. The results 
of the present study, when compared to the studies of the authors 
discussed above, have similar outcome with respect to the onset and 
duration of sensory and motor block, the duration of analgesia and 
hemodynamic profile. 
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SUMMARY 
To summarize, intrathecal dexmedetomidine added to bupivacaine had 
a dose dependent effect on the sensory and motor block characteristics 
showing 
1. earlier onset of sensory and motor blockade 
2. increased initial segmental level of sensory blockade  
3. increased duration of sensory and motor blockade 
4. increased duration of post-op. analgesia 
5. increased level of sedation 
Three different doses (5, 10 and 15µg) did not vary in their effect on the 
hemodynamic stability or adverse effects. 
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CONCLUSION 
Intrathecal dexmedetomidine added to bupivacaine for lower 
abdominal surgeries, has a dose dependent effect on the sensory and 
motor blockade, with earlier onset and increased duration of blockade and 
prolonged post-operative analgesia, better level of sedation and stable 
hemodynamics. 
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PROFORMA 
A COMPARISON BETWEEN THREE DIFFERENT DOSES OF 
INTRATHECAL DEXMEDETOMIDINE ADDED TO HYPERBARIC 
BUPIVACAINE FOR INFRA UMBILICAL SURGERIES 
Name:         Diagnosis: 
Age:        Procedure: 
IP No.:       ASA Grade: 
Pre-Operative Evaluation: 
Pulse:        Airway: 
BP:        CVS: 
RR:        RS: 
Pre-Operative Investigation: 
Hb%:        Blood Urea: 
BT:        Sr. Creatinine: 
CT:        Chest X-ray: 
RBS:        ECG: 
Blood Grouping & Typing: 
ANAESTHETIC PLAN 
1. Pre-loading 
IV Infusion of Ringer Lactate (20ml/kg) 
2. Sub Arachnoid Block 
• Position: Right Lateral - Supine 
• Space:    L3-L4 
• Needle size: 26G Quincke’s needle 
• No. of attempts & Pass: 
• Paraesthesia: YES / NO  
• Trauma/Bloody tap: YES / NO 
3. Drugs 
Group A: 12mg (2.4 ml) of 0.5% hyperbaric bupivacaine + 5 µg of 
dexmedetomidine in 0.6 ml of NS 
Group B: 12mg (2.4 ml) of 0.5% hyperbaric bupivacaine + 10 µg of 
dexmedetomidine in 0.6 ml of NS 
Group C: 12mg (2.4 ml) of 0.5% hyperbaric bupivacaine + 15 µg of 
dexmedetomidine in 0.6 ml of NS 
4. Sensory block assessed bilaterally by analgesia to pin-prick with 
hypodermic needle in mid clavicular line. 
 
 
Sensory Block:  
Onset of sensory block (sec) 
Sensory regression time to S1 (min) 
Maximum sensory level  
Duration of sensory block (min) 
Motor Block: 
Assessed using modified bromage scale. 
Grade 
0 -No motor block 
1 –Inability to raise extended legs 
2 –Inability to flex knee joints 
3 –Inability to flex ankle joints 
 Onset of motor block (sec) 
Duration of motor block (min): It is the time from the onset of complete motor 
blockade to motor regression to  bromage scale 0. 
5. Duration of Surgery 
6. Rescue analgesia – Inj. Diclofenac Sodium – 75 mg IM 
7. Duration of analgesia (min) 
Assessed using visual analoug scale 
0-1                      EXCELLENT    
2-4                      GOOD 
5-6                       FAIR 
7-8                       POOR 
9-10                     NO RELIEF 
If pain score is more than 4, supplementary analgesia to be given. 
PARAMETERS MONITORED 
I. Hemodynamic parameters 
Time 
(min/hr) 
PR SBP DBP MAP SPO2 RR 
0 min       
5 min       
10 min       
15 min 
20 min 
      
30 min       
45 min       
60 min       
90 min       
120 min       
3 hr       
4 hr       
8 hr       
12 hr       
16 hr       
20 hr       
24 hr       
 
Medication: Inj. Atropine 0.6 mg i.v if PR <60/min. 
If systolic blood pressure <90mm Hg or >20% decrease in baseline 
MAP values; inj. Ephedrine 6mg i.v and fluids given 
 
II. Two Segment Regression Time (min.): 
Time to 2 segment regression 
 
 
 
 
III. Visual Analogue Pain Scale VAS (0-10 point) Scale 
Time 
 
VAS Score 
2 hr  
3 hr  
4 hr  
8 hr  
12 hr  
 
 
 
 
 
IV. Sedation 
Assessed using Ramsay Sedation score 
 
  
 
 
 
 
 
Grade Description 
1 Anxious and agitated 
2 Cooperative and tranquil 
3 Drowsy but responsive to command 
4 Asleep but responsive to a glabellar tap 
5 Asleep with a sluggish response to tactile 
stimulation 
6 Asleep and no response 
Time 
 
Sedation Score 
1 hr  
2 hr  
3 hr  
4 hr  
8 hr  
12 hr  
 
V. ADVERSE  EFFECTS 
Hypotension  
Bradycardia  
Nausea & Vomiting  
Urinary retention  
Pruritus  
Respiratory depression  
 
SNO GR.     NAME AGE SEX IP.NO ASA
0 
MIN
5 
MIN
10 
MIN
15 
MIN
20 
MIN
30 
MIN
45 
MIN
60 
MIN
90 
MIN
120 
MIN
3 
HR
4 
HR 8 HR
12 
HR
16 
HR
20 
HR
24 
HR
ATR
OPIN
E
0 
MIN
5 
MIN
10 
MIN
15 
MIN
20 
MIN
  30 
MIN
  45 
MIN
  60 
MIN
   90 
MIN
  
120 
MIN
 3 
HR
  4 
HR
  8 
HR
 12 
HR
  16 
HR
20 
HR
24 
HR
0 
MIN
5 
MIN
10 
MIN
15 
MIN
1 A ABDUL KHADAR 59 MALE 35988 2 82 80 78 76 80 84 86 80 78 78 76 76 80 80 82 84 88 NIL 100 99 98 100 100 99 100 100 100 100 100 100 100 99 100 100 100 120 110 110 100
2 A KARUPU SWAMY 35 MALE 29972 2 82 74 72 70 72 70 70 74 78 78 80 82 82 82 82 82 82 NIL 100 100 99 100 99 100 100 99 100 100 100 100 100 100 100 100 100 110 110 110 110
3 A MUSTAFA 32 MALE 31057 1 82 80 80 80 80 82 80 84 84 84 84 84 84 84 84 84 84 NIL 99 100 99 100 100 99 100 100 100 100 100 100 100 100 100 100 100 110 110 110 100
4 A SANKAR 26 MALE 26417 1 78 74 72 72 72 74 74 74 72 72 72 74 76 76 78 78 78 NIL 100 100 99 100 99 100 100 100 100 100 99 100 100 100 100 100 100 110 100 100 100
5 A MURUGAN 34 MALE 23057 1 86 84 82 70 68 72 74 72 72 70 68 70 68 70 70 72 70 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 110 100 100 90
6 A VELLATHAI 56 FEMALE 59311 2 72 69 69 69 57 63 60 64 60 59 68 64 64 68 68 72 72 YES 99 99 98 98 100 100 100 100 100 100 100 100 100 100 100 100 100 140 130 120 120
7 A SHANMUGAVEL 55 MALE 32488 2 78 76 70 70 70 72 74 76 72 68 76 80 80 82 82 82 84 NIL 99 99 98 98 100 98 100 100 100 100 100 100 100 100 100 100 100 110 110 100 100
8 A ARUMUGHAM 54 MALE 31057 2 74 76 74 72 72 78 76 72 72 72 72 70 78 80 80 82 82 NIL 100 100 99 100 99 99 100 100 100 100 100 100 100 100 100 100 100 130 120 110 100
9 A MANI 58 MALE 33694 1 72 68 68 72 74 72 72 68 68 70 70 70 70 70 70 72 72 NIL 100 100 99 100 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 90 90
10 A THOMAS 35 MALE 34833 1 82 80 78 76 80 84 86 80 78 78 76 76 80 80 82 84 88 NIL 100 100 99 100 100 100 100 100 100 100 100 100 100 100 99 100 100 120 110 110 100
11 A PARVATHI 42 FEMALE 4329 2 82 74 72 70 72 70 70 74 78 78 80 82 82 82 82 82 82 NIL 100 99 98 98 99 100 100 100 100 100 100 100 100 100 100 100 100 110 110 110 110
12 A ALLITHURAI 26 MALE 34849 1 82 80 80 80 80 82 80 84 84 84 84 84 84 84 84 84 84 NIL 100 100 99 99 99 99 100 100 100 100 100 100 100 100 100 100 100 110 110 110 100
13 A LEKSHMI 52 FEMALE 32592 2 78 74 72 72 72 74 74 74 72 72 72 74 76 76 78 78 78 NIL 100 100 99 100 100 99 100 99 100 100 100 100 100 100 100 100 100 110 100 100 100
14 A ANPALAGAN 35 MALE 34866 1 86 84 82 70 68 72 74 72 72 70 68 70 68 70 70 72 70 NIL 100 99 98 98 99 100 100 100 99 100 100 100 100 100 100 100 100 110 100 100 90
15 A SIVAKAMI 46 FEMALE 39054 1 72 69 69 69 57 63 60 64 60 59 68 64 64 68 68 72 72 NIL 100 100 99 100 100 100 99 100 100 100 100 99 100 100 100 100 100 140 130 120 120
16 A SITALEKSHMI 45 FEMALE 41182 2 78 76 70 70 70 72 74 76 72 68 76 80 80 82 82 82 84 NIL 100 100 99 99 100 100 100 100 100 100 100 100 100 100 100 100 100 110 110 100 100
17 A MUPPIDATI 42 FEMALE 42110 1 74 76 74 72 72 78 76 72 72 72 72 70 78 80 80 82 82 NIL 99 100 99 99 100 100 100 100 100 100 100 100 100 100 100 100 100 130 120 110 100
18 A KASINADAN 50 MALE 33752 2 72 68 68 72 74 72 72 68 68 70 70 70 70 70 70 72 72 NIL 100 99 99 99 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 90 90
19 A SHANMUAVADIVU 56 FEMALE 33753 2 82 80 78 76 80 84 86 80 78 78 76 76 80 80 82 84 88 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 120 120 120
20 A ULAGARANI 49 FEMALE 38702 2 82 74 72 70 72 70 70 74 78 78 80 82 82 82 82 82 82 NIL 100 100 99 100 100 100 100 99 100 100 100 100 100 100 100 100 100 130 130 120 100
 HR SBP
MASTER CHART: GROUP 'A' ‐ BUPIVACAINE WITH 5µg DEXMEDETOMIDINE
SPO2
SNO GR.     NAME AGE SEX IP.NO ASA
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21 B RAMASWAMY 39 MALE 33499 1 80 90 90 90 80 80 90 70 80 84 84 84 76 76 76 78 80 NIL 99 100 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 100 100 100
22 B MARIAMMAL 35 FEMALE 37928 2 90 88 86 86 86 80 80 80 82 82 82 82 84 84 84 84 84 NIL 100 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 120 120 110 110
23 B LEKSHMI 50 FEMALE 39018 2 80 82 84 88 84 86 82 88 86 84 82 88 82 84 88 88 88 NIL 100 99 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 108 110 110
24 B MARIAPPAN 40 MALE 38700 1 88 84 80 78 80 82 84 88 84 84 82 80 80 78 78 84 84 NIL 99 100 99 98 100 100 100 100 100 100 100 100 100 100 100 100 100 120 110 110 100
25 B BHAGAVATHI 48 FEMALE 4408 1 92 88 86 90 84 82 90 88 88 90 92 84 86 88 84 84 84 NIL 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 110 110 110
26 B SARASWATI 50 FEMALE 4431 2 78 74 68 58 58 60 58 64 68 72 74 74 72 74 74 76 76 YES 100 99 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 110 110 110 100
27 B ARULRAJ 48 MALE 34715 1 102 100 94 94 90 88 86 90 88 92 92 94 94 92 92 90 90 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 100 100 100
28 B PANDIRAJAN 39 MALE 34623 1 108 112 114 108 106 104 106 98 98 96 94 98 100 102 102 104 104 NIL 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 100 100 90
29 B KALAISELVI 46 FEMALE 5857 1 78 74 76 72 70 73 78 78 78 80 82 78 74 68 68 68 70 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 140 130 120 120
30 B KAMARAJ 48 MALE 33295 1 98 96 98 94 94 92 92 90 94 90 90 90 90 88 88 88 86 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 110 100 100
31 B AMIRTHARANI 45 FEMALE 41163 2 112 108 106 108 108 98 98 96 96 94 92 92 94 94 92 92 94 NIL 99 100 99 98 100 100 100 100 100 100 100 100 100 100 100 100 100 130 120 110 100
32 B MUTHUKARUPPAN 54 MALE 33210 1 88 86 84 82 82 80 78 78 76 76 78 80 80 80 82 82 82 NIL 100 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 90 90
33 B MURUGAN 55 MALE 31529 2 98 96 90 90 88 88 86 86 88 86 86 80 84 86 86 84 84 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 120 110 110 100
34 B MANONMANI 42 FEMALE 42023 1 84 80 78 74 70 68 68 70 72 72 74 70 70 78 78 76 76 NIL 100 100 99 98 100 100 100 100 100 100 100 100 99 100 100 100 100 110 110 110 110
35 B ABDUL KHASIM 51 MALE 32714 1 72 68 68 70 68 70 74 72 72 70 70 74 74 78 74 74 72 NIL 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 100 100 110 110 110 100
36 B KUMAR 38 MALE 31240 1 96 94 92 92 92 98 100 102 108 100 98 98 96 96 98 98 96 NIL 100 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 110 100 100 100
37 B SANTHOSAM 45 FEMALE 39003 1 84 80 78 76 74 76 74 72 72 70 76 76 74 74 72 72 72 NIL 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 100 100 90
38 B KANMANI 49 FEMALE 36928 2 84 80 78 70 68 68 70 64 64 68 68 68 68 68 66 68 68 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 140 130 120 120
39 B RAJAMANI 52 MALE 31285 1 78 74 70 72 78 78 76 80 82 84 86 88 88 86 86 86 88 NIL 100 99 100 99 100 100 100 100 99 100 100 100 100 100 99 100 100 110 110 100 100
40 B PANDIAMMAL 46 FEMALE 5383 1 90 88 86 86 88 86 84 84 82 82 80 80 80 84 84 84 82 NIL 100 99 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 120 110 100
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MASTER CHART: GROUP 'B' ‐ BUPIVACAINE WITH 10µg DEXMEDETOMIDINE
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41 C MUTHUMALAI 50 FEMALE 4401 2 92 82 86 92 82 86 90 90 88 92 95 92 88 84 84 84 88 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 120 110 100
42 C PAVANASAM 33 MALE 51238 1 77 76 74 69 68 69 70 72 74 74 70 72 72 72 72 72 74 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 110 110 106
43 C RAJAMMAL 45 FEMALE 56546 1 75 68 70 67 64 63 66 64 69 58 58 64 64 70 70 70 72 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 149 130 108 103
44 C MARIAMMAL 45 FEMALE 55539 1 120 116 98 98 96 90 80 80 70 74 76 90 88 84 80 80 80 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 120 110 110 100
45 C SUMSUDIN 49 MALE 47549 2 85 70 70 70 65 65 60 70 60 68 70 71 70 70 72 72 72 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 150 160 120 120
46 C RAMACHANDRAN 19 MALE 50397 2 92 96 94 94 92 88 75 75 62 71 78 74 74 72 72 74 74 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 87 123 106
47 C VELSAMY 43 MALE 53937 1 91 78 73 84 73 61 64 68 60 64 68 72 68 74 68 68 72 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 155 155 147 146
48 C MARIYAL 42 FEMALE 41441 2 74 68 58 58 60 58 60 62 64 68 68 68 64 68 68 74 74 YES 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 120 100 100 90
49 C PERUMAL 48 MALE 39055 1 102 100 100 90 90 90 102 98 80 86 88 88 90 90 100 98 98 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 110 120 110
50 C JOTHI 35 FEMALE 33509 1 80 78 70 60 70 70 70 68 68 70 68 68 68 70 68 68 68 NIL 100 98 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 100 110 98
51 C ESAKI MUTHU 45 MALE 39669 1 84 90 92 82 90 84 90 82 82 80 80 82 86 84 88 86 84 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 110 110 110
52 C MANI 49 MALE 39601 1 80 78 74 72 70 68 70 68 72 76 72 74 70 76 70 70 72 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 110 110 110
53 C PITCHAMMAL 45 FEMALE 38118 2 78 76 76 74 74 76 78 76 72 72 70 70 70 72 72 72 74 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 130 110 90 86
54 C LEKSHMIAMMAL 55 FEMALE 40195 2 78 74 68 60 58 58 60 54 60 62 64 62 62 62 64 64 64 YES 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 150 160 120 120
55 C CHELAPPAN 46 MALE 34201 1 106 106 104 102 100 98 102 102 104 104 104 106 100 100 100 100 102 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 87 123 106
56 C SULAIMAN 40 MALE 324102 1 92 88 86 86 84 88 86 84 84 86 88 88 88 88 88 86 88 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 155 155 147 146
57 C GANDHIMATHI 50 FEMALE 37142 1 84 82 78 78 76 76 78 80 82 84 86 88 86 88 84 88 86 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 120 110 90 90
58 C MANIAMMAL 46 FEMALE 39140 2 68 74 68 72 78 80 82 84 88 82 84 84 82 82 84 84 84 NIL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 110 110 110 106
59 C MUTHIAH 49 MALE 30119 1 84 82 82 78 82 84 86 88 90 92 94 94 96 98 100 102 102 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 149 130 108 103
60 C PALAMMAL 54 FEMALE 39141 78 76 74 74 72 78 78 78 74 76 78 80 80 80 80 80 84 NIL 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 120 110 110 100
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MASTER CHART: GROUP 'C' ‐ BUPIVACAINE WITH 15µg DEXMEDETOMIDINE
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1 A ABDUL KHADAR 59 MALE 35988 2 100 100 90 100 100 100 100 100 100 100 100 100 100 80 70 70 70 70 68 72 74 76 78 78 80 80 82 82 82 82 90 88 86 84 84 84
2 A KARUPU SWAMY 35 MALE 29972 2 120 110 120 130 120 120 120 120 110 110 110 100 100 66 66 66 68 68 68 68 60 70 70 70 74 74 74 74 74 74 90 90 90 90 90 90
3 A MUSTAFA 32 MALE 31057 1 100 100 100 100 110 110 110 110 110 110 110 110 110 70 72 72 70 70 74 70 72 70 72 74 74 74 74 74 74 74 82 82 82 82 82 82
4 A SANKAR 26 MALE 26417 1 100 100 100 100 110 110 110 110 110 110 110 110 110 80 70 72 70 72 70 70 70 72 80 80 80 80 80 80 80 80 90 80 80 80 80 80
5 A MURUGAN 34 MALE 23057 1 80 100 80 100 100 100 100 100 100 100 100 100 100 90 80 80 70 64 70 64 70 70 70 70 70 70 70 70 70 70 90 80 80 70 64 70
6 A VELLATHAI 56 FEMALE 59311 2 120 130 130 140 140 150 150 120 120 130 130 130 130 80 80 80 80 80 80 80 80 90 80 80 80 80 80 80 80 80 100 96 92 92 92 96
7 A SHANMUGAVEL 55 MALE 32488 2 100 100 90 90 110 110 110 100 100 100 100 100 100 80 80 70 70 70 70 60 60 70 80 80 70 70 70 70 70 70 90 90 80 80 80 80
8 A ARUMUGHAM 54 MALE 31057 2 100 100 100 110 110 110 110 120 120 120 120 120 120 90 80 80 60 60 60 70 70 70 70 70 80 80 80 80 80 80 103 94 73 73 73 80
9 A MANI 58 MALE 33694 1 100 100 96 96 100 100 100 100 100 106 106 106 110 70 70 60 60 60 60 60 60 66 66 70 70 70 66 66 68 68 80 80 70 70 73 73
10 A THOMAS 35 MALE 34833 1 100 100 90 100 100 100 100 100 100 100 100 100 100 80 70 70 70 70 68 72 74 76 78 78 80 80 82 82 82 82 90 88 86 84 84 84
11 A PARVATHI 42 FEMALE 4329 2 120 110 120 130 120 120 120 120 110 110 110 100 100 66 66 66 68 68 68 68 60 70 70 70 74 74 74 74 74 74 90 90 90 90 90 90
12 A ALLITHURAI 26 MALE 34849 1 100 100 100 100 110 110 110 110 110 110 110 110 110 70 72 72 70 70 74 70 72 70 72 74 74 74 74 74 74 74 82 82 82 82 82 82
13 A LEKSHMI 52 FEMALE 32592 2 100 100 100 100 110 110 110 110 110 110 110 110 110 80 70 72 70 72 70 70 70 72 80 80 80 80 80 80 80 80 90 80 80 80 80 80
14 A ANPALAGAN 35 MALE 34866 1 80 100 80 100 100 100 100 100 100 100 100 100 100 90 80 80 70 64 70 64 70 70 70 70 70 70 70 70 70 70 90 80 80 70 64 70
15 A SIVAKAMI 46 FEMALE 39054 1 120 130 130 140 140 150 150 120 120 130 130 130 130 80 80 80 80 80 80 80 80 90 80 80 80 80 80 80 80 80 100 96 92 92 92 96
16 A SITALEKSHMI 45 FEMALE 41182 2 100 100 90 90 110 110 110 100 100 100 100 100 100 80 80 70 70 70 70 60 60 70 80 80 70 70 70 70 70 70 90 90 80 80 80 80
17 A MUPPIDATI 42 FEMALE 42110 1 100 100 100 110 110 110 110 120 120 120 120 120 120 90 80 80 60 60 60 70 70 70 70 70 80 80 80 80 80 80 103 94 73 73 73 80
18 A KASINADAN 50 MALE 33752 2 100 100 96 96 100 100 100 100 100 106 106 106 110 70 70 60 60 60 60 60 60 66 66 70 70 70 66 66 68 68 80 80 70 70 73 73
19 A SHANMUAVADIVU 56 FEMALE 33753 2 110 110 110 110 110 110 110 110 110 110 110 110 110 80 80 80 80 70 70 70 70 70 70 70 70 70 70 70 70 70 96 93 93 93 83 83
20 A ULAGARANI 49 FEMALE 38702 2 100 90 90 100 100 96 96 100 100 100 100 106 106 80 80 80 70 70 60 60 60 60 60 60 66 66 70 70 66 66 96 96 93 80 80 70
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MASTER CHART: GROUP 'A' ‐ BUPIVACAINE WITH 5µg DEXMEDETOMIDINE
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21 B RAMASWAMY 39 MALE 33499 1 100 100 100 110 110 110 120 120 120 120 120 120 120 80 80 80 70 60 50 50 60 60 60 70 70 70 70 70 70 70 70 68 70 64 68 70
22 B MARIAMMAL 35 FEMALE 37928 2 110 106 106 110 108 108 100 110 100 100 100 100 100 80 80 80 80 80 70 70 70 66 60 73 73 83 79 78 78 78 93 93 91 90 91 82
23 B LEKSHMI 50 FEMALE 39018 2 100 110 110 110 108 108 110 110 110 108 110 120 120 70 70 52 52 62 70 70 70 70 70 68 68 68 68 70 70 72 82 80 74 74 77 90
24 B MARIAPPAN 40 MALE 38700 1 100 100 90 100 100 100 100 100 100 100 100 100 100 80 70 70 70 70 68 72 74 76 78 78 80 80 82 82 82 82 90 88 86 84 84 84
25 B BHAGAVATHI 48 FEMALE 4408 1 120 110 120 130 120 120 120 120 110 110 110 100 100 66 66 66 68 68 68 68 60 70 70 70 74 74 74 74 74 74 90 90 90 90 90 90
26 B SARASWATI 50 FEMALE 4431 2 100 100 100 100 110 110 110 110 110 110 110 110 110 70 72 72 70 70 74 70 72 70 72 74 74 74 74 74 74 74 82 82 82 82 82 82
27 B ARULRAJ 48 MALE 34715 1 100 100 100 100 110 110 110 110 110 110 110 110 110 80 70 72 70 72 70 70 70 72 80 80 80 80 80 80 80 80 90 80 80 80 80 80
28 B PANDIRAJAN 39 MALE 34623 1 80 100 80 100 100 100 100 100 100 100 100 100 100 90 80 80 70 64 70 64 70 70 70 70 70 70 70 70 70 70 90 80 80 70 64 70
29 B KALAISELVI 46 FEMALE 5857 1 120 130 130 140 140 150 150 120 120 130 130 130 130 80 80 80 80 80 80 80 80 90 80 80 80 80 80 80 80 80 100 96 92 92 92 96
30 B KAMARAJ 48 MALE 33295 1 100 100 90 90 110 110 110 100 100 100 100 100 100 80 80 70 70 70 70 60 60 70 80 80 70 70 70 70 70 70 90 90 80 80 80 80
31 B AMIRTHARANI 45 FEMALE 41163 2 100 100 100 110 110 110 110 120 120 120 120 120 120 90 80 80 60 60 60 70 70 70 70 70 80 80 80 80 80 80 103 94 73 73 73 80
32 B MUTHUKARUPPAN 54 MALE 33210 1 100 100 96 96 100 100 100 100 100 106 106 106 110 70 70 60 60 60 60 60 60 66 66 70 70 70 66 66 68 68 80 80 70 70 73 73
33 B MURUGAN 55 MALE 31529 2 100 100 90 100 100 100 100 100 100 100 100 100 100 80 70 70 70 70 68 72 74 76 78 78 80 80 82 82 82 82 90 88 86 84 84 84
34 B MANONMANI 42 FEMALE 42023 1 120 110 120 130 120 120 120 120 110 110 110 100 100 66 66 66 68 68 68 68 60 70 70 70 74 74 74 74 74 74 90 90 90 90 90 90
35 B ABDUL KHASIM 51 MALE 32714 1 100 100 100 100 110 110 110 110 110 110 110 110 110 70 72 72 70 70 74 70 72 70 72 74 74 74 74 74 74 74 82 82 82 82 82 82
36 B KUMAR 38 MALE 31240 1 100 100 100 100 110 110 110 110 110 110 110 110 110 80 70 72 70 72 70 70 70 72 80 80 80 80 80 80 80 80 90 80 80 80 80 80
37 B SANTHOSAM 45 FEMALE 39003 1 80 100 80 100 100 100 100 100 100 100 100 100 100 90 80 80 70 64 70 64 70 70 70 70 70 70 70 70 70 70 90 80 80 70 64 70
38 B KANMANI 49 FEMALE 36928 2 120 130 130 140 140 150 150 120 120 130 130 130 130 80 80 80 80 80 80 80 80 90 80 80 80 80 80 80 80 80 100 96 92 92 92 96
39 B RAJAMANI 52 MALE 31285 1 100 100 90 90 110 110 110 100 100 100 100 100 100 80 80 70 70 70 70 60 60 70 80 80 70 70 70 70 70 70 90 90 80 80 80 80
40 B PANDIAMMAL 46 FEMALE 5383 1 100 100 100 110 110 110 110 120 120 120 120 120 120 90 80 80 60 60 60 70 70 70 70 70 80 80 80 80 80 80 103 94 73 73 73 80
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MASTER CHART: GROUP 'B' ‐ BUPIVACAINE WITH 10µg DEXMEDETOMIDINE
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41 C MUTHUMALAI 50 FEMALE 4401 2 100 100 100 110 110 110 110 120 120 120 120 120 120 90 80 80 60 60 60 70 70 70 70 70 80 80 80 80 80 80 103 94 73 73 73 80
42 C PAVANASAM 33 MALE 51238 1 110 100 100 100 10 110 110 100 100 100 100 100 100 70 70 60 60 60 60 60 60 60 60 60 60 60 60 60 70 70 83 83 78 77 78 78
43 C RAJAMMAL 45 FEMALE 56546 1 100 128 118 113 120 103 100 100 100 100 110 110 110 88 72 58 53 51 76 63 57 63 53 70 70 70 70 70 70 70 110 92 78 70 72 99
44 C MARIAMMAL 45 FEMALE 55539 1 100 120 110 110 110 100 110 110 100 110 110 110 110 80 80 80 80 90 90 90 80 80 80 80 80 70 80 70 70 70 93 90 90 86 93 100
45 C SUMSUDIN 49 MALE 47549 2 120 120 130 120 118 138 130 120 120 110 120 120 130 90 89 74 75 70 70 75 75 75 71 70 72 70 68 70 75 80 106 105 101 93 92 92
46 C RAMACHANDRAN 19 MALE 50397 2 98 100 102 105 101 111 151 110 110 110 110 110 110 67 55 64 57 58 59 54 55 52 71 85 70 70 70 67 67 70 81 69 82 77 75 87
47 C VELSAMY 43 MALE 53937 1 141 153 117 139 127 117 100 100 117 110 110 100 110 87 87 92 83 75 119 86 70 49 86 70 70 86 70 70 70 70 112 112 116 106 108 139
48 C MARIYAL 42 FEMALE 41441 2 90 100 100 100 90 110 110 100 100 110 110 110 110 80 70 70 60 60 70 70 70 60 72 72 70 70 72 72 72 72 93 80 80 70 70 80
49 C PERUMAL 48 MALE 39055 1 110 110 98 90 88 90 90 90 100 100 100 100 100 80 70 70 60 60 60 60 60 60 60 60 68 68 68 68 60 60 80 80 80 80 80 74
50 C JOTHI 35 FEMALE 33509 1 110 120 110 100 100 100 100 104 104 110 110 110 110 80 80 70 60 70 70 70 70 72 72 68 68 68 68 70 70 70 80 83 73 83 93 85
51 C ESAKI MUTHU 45 MALE 39669 1 100 100 100 102 110 110 110 108 108 120 120 120 120 80 72 70 70 70 70 70 72 72 80 80 80 80 80 80 80 80 96 90 86 83 80 80
52 C MANI 49 MALE 39601 1 100 100 100 100 110 110 110 110 110 110 120 120 120 80 80 74 70 70 70 70 70 70 70 72 70 80 80 80 82 80 96 90 86 83 80 80
53 C PITCHAMMAL 45 FEMALE 38118 2 90 100 100 100 110 110 110 110 110 110 120 120 120 80 80 60 55 60 70 70 70 70 70 72 70 80 80 80 82 80 96 90 70 65 70 80
54 C LEKSHMIAMMAL 55 FEMALE 40195 2 120 120 130 120 118 138 130 120 120 110 120 120 130 90 89 74 75 70 70 75 75 75 71 70 72 70 68 70 75 80 106 105 101 93 92 92
55 C CHELAPPAN 46 MALE 34201 1 98 100 102 105 101 111 151 110 110 110 110 110 110 67 55 64 57 58 59 54 55 52 71 85 70 70 70 67 67 70 81 69 82 77 75 87
56 C SULAIMAN 40 MALE 324102 1 141 153 117 139 127 117 100 100 117 110 110 100 110 87 87 92 83 75 119 86 70 49 86 70 70 86 70 70 70 70 112 112 116 106 108 139
57 C GANDHIMATHI 50 FEMALE 37142 1 88 90 100 100 100 100 110 110 110 100 100 100 100 80 80 60 60 60 60 80 80 80 80 70 70 70 70 70 70 70 93 90 70 70 69 70
58 C MANIAMMAL 46 FEMALE 39140 2 110 100 100 100 10 110 110 100 100 100 100 100 100 70 70 60 60 60 60 60 60 60 60 60 60 60 60 60 70 70 83 83 78 77 78 78
59 C MUTHIAH 49 MALE 30119 1 100 128 118 113 120 103 100 100 100 100 110 110 110 88 72 58 53 51 76 63 57 63 53 70 70 70 70 70 70 70 110 92 78 70 72 99
60 C PALAMMAL 54 FEMALE 39141 100 120 110 110 110 100 110 110 100 110 110 110 110 80 80 80 80 90 90 90 80 80 80 80 80 70 80 70 70 70 93 90 90 86 93 100
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MASTER CHART: GROUP 'C' ‐ BUPIVACAINE WITH 15µg DEXMEDETOMIDINE
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1 A ABDUL KHADAR 59 MALE 35988 2 84 84 88 88 88 88 84 84 88 88 88 NIL 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 250 180 T8 3 180 65
2 A KARUPU SWAMY 35 MALE 29972 2 90 98 96 98 98 94 96 98 92 98 96 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 240 230 T6 3 105 75
3 A MUSTAFA 32 MALE 31057 1 80 80 80 80 80 80 80 80 80 80 80 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 220 240 T8 3 110 60
4 A SANKAR 26 MALE 26417 1 80 80 80 90 90 90 90 90 90 90 90 NIL 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 200 200 T8 3 125 68
5 A MURUGAN 34 MALE 23057 1 64 70 70 70 70 70 70 70 70 70 72 YES 18 20 20 20 20 18 18 18 16 18 18 18 18 20 20 20 20 220 210 T8 3 130 75
6 A VELLATHAI 56 FEMALE 59311 2 96 100 106 93 93 92 92 96 96 96 96 NIL 16 16 16 16 16 18 18 18 18 20 20 20 20 20 20 20 18 185 250 T8 3 180 180
7 A SHANMUGAVEL 55 MALE 32488 2 70 70 83 90 90 83 83 83 80 80 80 NIL 18 18 18 18 18 20 20 20 20 18 18 18 20 20 20 22 22 195 255 T8 3 300 90
8 A ARUMUGHAM 54 MALE 31057 2 80 80 80 80 94 94 94 94 94 94 94 NIL 20 20 20 20 22 22 22 24 24 22 18 18 18 20 20 20 20 210 270 T6 3 260 80
9 A MANI 58 MALE 33694 1 72 72 77 77 80 80 80 79 79 80 80 NIL 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 200 230 T7 3 110 68
10 A THOMAS 35 MALE 34833 1 84 84 88 88 88 88 84 84 88 88 88 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 190 240 T8 3 140 75
11 A PARVATHI 42 FEMALE 4329 2 90 98 96 98 98 94 96 98 92 98 96 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 220 200 T8 3 120 130
12 A ALLITHURAI 26 MALE 34849 1 80 80 80 80 80 80 80 80 80 80 80 NIL 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 210 210 T8 3 110 80
13 A LEKSHMI 52 FEMALE 32592 2 80 80 80 90 90 90 90 90 90 90 90 NIL 18 20 20 20 20 18 18 18 16 18 18 18 18 20 20 20 20 240 245 T6 3 125 140
14 A ANPALAGAN 35 MALE 34866 1 64 70 70 70 70 70 70 70 70 70 72 NIL 16 16 16 16 16 18 18 18 18 20 20 20 20 20 20 20 18 280 260 T6 3 130 65
15 A SIVAKAMI 46 FEMALE 39054 1 96 100 106 93 93 92 92 96 96 96 96 NIL 18 18 18 18 18 20 20 20 20 18 18 18 20 20 20 22 22 290 250 T6 3 180 140
16 A SITALEKSHMI 45 FEMALE 41182 2 70 70 83 90 90 83 83 83 80 80 80 NIL 20 20 20 20 22 22 22 24 24 22 18 18 18 20 20 20 20 246 260 T8 3 150 120
17 A MUPPIDATI 42 FEMALE 42110 1 80 80 80 80 94 94 94 94 94 94 94 NIL 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 230 240 T8 3 110 136
18 A KASINADAN 50 MALE 33752 2 72 72 77 77 80 80 80 79 79 80 80 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 260 230 T8 3 200 75
19 A SHANMUAVADIVU 56 FEMALE 33753 2 83 83 83 83 83 83 83 83 83 83 83 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 210 235 T8 3 210 120
20 A ULAGARANI 49 FEMALE 38702 2 70 73 73 72 72 77 77 80 80 79 79 NIL 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 225 225 T7 3 130 110
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21 B RAMASWAMY 39 MALE 33499 1 62 77 82 75 86 86 86 86 86 86 86 YES 18 20 20 20 20 18 18 18 16 18 18 18 18 20 20 20 20 180 180 T6 3 145 75
22 B MARIAMMAL 35 FEMALE 37928 2 82 83 80 76 83 85 88 85 86 86 86 NIL 16 16 16 16 16 18 18 18 18 20 20 20 20 20 20 20 18 240 220 T6 3 130 160
23 B LEKSHMI 50 FEMALE 39018 2 84 94 90 85 85 82 86 84 88 90 91 NIL 18 18 18 18 18 20 20 20 20 18 18 18 20 20 20 22 22 200 225 T8 3 110 120
24 B MARIAPPAN 40 MALE 38700 1 84 84 88 88 88 88 84 84 88 88 88 NIL 20 20 20 20 22 22 22 24 24 22 18 18 18 20 20 20 20 185 215 T7 3 140 68
25 B BHAGAVATHI 48 FEMALE 4408 1 90 98 96 98 98 94 96 98 92 98 96 NIL 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 200 240 T7 3 135 110
26 B SARASWATI 50 FEMALE 4431 2 80 80 80 80 80 80 80 80 80 80 80 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 240 245 T7 3 160 140
27 B ARULRAJ 48 MALE 34715 1 80 80 80 90 90 90 90 90 90 90 90 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 250 250 T8 3 180 90
28 B PANDIRAJAN 39 MALE 34623 1 64 70 70 70 70 70 70 70 70 70 72 YES 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 190 220 T8 3 160 80
29 B KALAISELVI 46 FEMALE 5857 1 96 100 106 93 93 92 92 96 96 96 96 NIL 18 20 20 20 20 18 18 18 16 18 18 18 18 20 20 20 20 210 230 T8 3 145 136
30 B KAMARAJ 48 MALE 33295 1 70 70 83 90 90 83 83 83 80 80 80 NIL 16 16 16 16 16 18 18 18 18 20 20 20 20 20 20 20 18 220 210 T4 3 200 65
31 B AMIRTHARANI 45 FEMALE 41163 2 80 80 80 80 94 94 94 94 94 94 94 NIL 18 18 18 18 18 20 20 20 20 18 18 18 20 20 20 22 22 195 220 T6 3 120 120
32 B MUTHUKARUPPAN 54 MALE 33210 1 72 72 77 77 80 80 80 79 79 80 80 NIL 20 20 20 20 22 22 22 24 24 22 18 18 18 20 20 20 20 200 240 T6 3 124 75
33 B MURUGAN 55 MALE 31529 2 84 84 88 88 88 88 84 84 88 88 88 NIL 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 190 210 T8 3 175 80
34 B MANONMANI 42 FEMALE 42023 1 90 98 96 98 98 94 96 98 92 98 96 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 210 230 T7 2 280 110
35 B ABDUL KHASIM 51 MALE 32714 1 80 80 80 80 80 80 80 80 80 80 80 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 180 240 T7 3 200 65
36 B KUMAR 38 MALE 31240 1 80 80 80 90 90 90 90 90 90 90 90 NIL 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 210 245 T6 3 120 70
37 B SANTHOSAM 45 FEMALE 39003 1 64 70 70 70 70 70 70 70 70 70 72 NIL 18 20 20 20 20 18 18 18 16 18 18 18 18 20 20 20 20 230 250 T8 3 110 126
38 B KANMANI 49 FEMALE 36928 2 96 100 106 93 93 92 92 96 96 96 96 NIL 16 16 16 16 16 18 18 18 18 20 20 20 20 20 20 20 18 200 235 T8 3 114 130
39 B RAJAMANI 52 MALE 31285 1 70 70 83 90 90 83 83 83 80 80 80 NIL 18 18 18 18 18 20 20 20 20 18 18 18 20 20 20 22 22 195 230 T7 3 126 68
40 B PANDIAMMAL 46 FEMALE 5383 1 80 80 80 80 94 94 94 94 94 94 94 NIL 20 20 20 20 22 22 22 24 24 22 18 18 18 20 20 20 20 210 230 T8 3 110 130
MEAN BP RR
MASTER CHART: GROUP 'B' ‐ BUPIVACAINE WITH 10µg DEXMEDETOMIDINE
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41 C MUTHUMALAI 50 FEMALE 4401 2 80 80 80 80 94 94 94 94 94 94 94 YES 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 200 215 T4 3 190 90
42 C PAVANASAM 33 MALE 51238 1 70 70 78 78 78 70 70 70 70 80 80 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 190 206 T6 3 180 90
43 C RAJAMMAL 45 FEMALE 56546 1 84 79 82 70 80 80 80 80 83 83 83 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 185 195 T4 3 200 110
44 C MARIAMMAL 45 FEMALE 55539 1 96 90 90 86 90 90 80 90 84 84 84 NIL 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 188 185 T7 3 180 90
45 C SUMSUDIN 49 MALE 47549 2 96 88 89 105 90 88 92 82 92 88 96 NIL 18 20 20 20 20 18 18 18 16 18 18 18 18 20 20 20 20 195 190 T6 3 165 150
46 C RAMACHANDRAN 19 MALE 50397 2 73 74 70 84 114 84 84 84 81 81 84 YES 16 16 16 16 16 18 18 18 18 20 20 20 20 20 20 20 18 210 185 T6 3 200 140
47 C VELSAMY 43 MALE 53937 1 104 94 85 104 80 80 104 84 84 80 84 NIL 18 18 18 18 18 20 20 20 20 18 18 18 20 20 20 22 22 220 190 T4 3 240 90
48 C MARIYAL 42 FEMALE 41441 2 80 80 70 84 84 80 80 84 84 84 84 NIL 20 20 20 20 22 22 22 24 24 22 18 18 18 20 20 20 20 180 195 T4 3 120 105
49 C PERUMAL 48 MALE 39055 1 74 75 75 76 76 74 74 72 72 70 69 NIL 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 195 220 T7 3 140 130
50 C JOTHI 35 FEMALE 33509 1 73 76 79 78 79 80 83 86 83 82 78 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 200 180 T6 3 146 146
51 C ESAKI MUTHU 45 MALE 39669 1 80 80 82 83 82 84 80 82 82 80 80 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 195 195 T6 3 130 70
52 C MANI 49 MALE 39601 1 80 80 83 83 84 83 90 90 93 94 93 NIL 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 210 196 T4 3 150 75
53 C PITCHAMMAL 45 FEMALE 38118 2 80 80 83 83 84 83 83 90 93 94 93 YES 18 20 20 20 20 18 18 18 16 18 18 18 18 20 20 20 20 185 210 T4 3 180 110
54 C LEKSHMIAMMAL 55 FEMALE 40195 2 96 88 89 105 90 88 92 82 92 88 96 NIL 16 16 16 16 16 18 18 18 18 20 20 20 20 20 20 20 18 190 187 T6 3 135 126
55 C CHELAPPAN 46 MALE 34201 1 73 74 70 84 114 84 84 84 81 81 84 NIL 18 18 18 18 18 20 20 20 20 18 18 18 20 20 20 22 22 210 190 T7 3 160 80
56 C SULAIMAN 40 MALE 324102 1 104 94 85 104 80 80 104 84 84 80 84 NIL 20 20 20 20 22 22 22 24 24 22 18 18 18 20 20 20 20 240 180 T6 3 180 90
57 C GANDHIMATHI 50 FEMALE 37142 1 86 86 86 86 83 83 83 80 80 80 80 NIL 18 16 18 20 20 18 18 18 18 20 18 18 18 20 18 18 18 195 170 T4 3 168 120
58 C MANIAMMAL 46 FEMALE 39140 2 70 70 78 78 78 70 70 70 70 80 80 NIL 18 18 16 18 18 18 20 20 16 18 18 20 20 18 18 18 18 180 180 T4 3 200 140
59 C MUTHIAH 49 MALE 30119 1 84 79 82 70 80 80 80 80 83 83 83 NIL 18 16 18 16 16 18 18 18 18 16 18 18 18 16 16 16 18 195 170 T8 3 180 75
60 C PALAMMAL 54 FEMALE 39141 96 90 90 86 90 90 80 90 84 84 84 NIL 18 20 20 20 20 22 22 22 20 20 20 18 18 18 18 18 18 180 170 T7 3 210 134
MEAN BP RR
MASTER CHART: GROUP 'C' ‐ BUPIVACAINE WITH 15µg DEXMEDETOMIDINE
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1 A ABDUL KHADAR 59 MALE 35988 2 2 2 2 2 2 2 2 210 240 0 0 4 260 nil nil nil nil nil
2 A KARUPU SWAMY 35 MALE 29972 2 2 2 2 2 2 2 2 200 260 0 0 2 4 480 nil nil nil nil nil
3 A MUSTAFA 32 MALE 31057 1 1 2 2 2 2 2 2 240 280 0 2 4 250 nil nil nil nil nil
4 A SANKAR 26 MALE 26417 1 1 2 2 2 2 2 2 190 290 0 0 4 300 nil nil nil nil nil
5 A MURUGAN 34 MALE 23057 1 2 3 2 2 2 2 2 210 240 0 0 2 4 480 YES nil nil nil nil
6 A VELLATHAI 56 FEMALE 59311 2 2 2 2 2 2 2 2 220 300 0 2 4 300 nil YES nil nil nil
7 A SHANMUGAVEL 55 MALE 32488 2 2 2 2 2 2 2 2 180 310 0 0 4 260 nil nil nil nil nil
8 A ARUMUGHAM 54 MALE 31057 2 2 2 2 2 2 2 2 240 260 0 0 2 4 480 nil nil nil nil nil
9 A MANI 58 MALE 33694 1 1 2 2 2 2 2 2 220 280 0 2 4 250 nil nil nil nil nil
10 A THOMAS 35 MALE 34833 1 1 2 2 2 2 2 2 210 300 0 0 4 300 nil nil nil nil nil
11 A PARVATHI 42 FEMALE 4329 2 2 3 2 2 2 2 2 200 310 0 0 2 4 480 nil nil nil nil nil
12 A ALLITHURAI 26 MALE 34849 1 2 2 2 2 2 2 2 220 300 0 2 4 300 nil nil nil nil nil
13 A LEKSHMI 52 FEMALE 32592 2 2 2 2 2 2 2 2 240 310 0 0 4 260 nil nil nil nil nil
14 A ANPALAGAN 35 MALE 34866 1 2 2 2 2 2 2 2 190 290 0 0 2 4 480 nil nil nil nil nil
15 A SIVAKAMI 46 FEMALE 39054 1 1 2 2 2 2 2 2 320 200 0 2 4 250 nil nil nil nil nil
16 A SITALEKSHMI 45 FEMALE 41182 2 1 2 2 2 2 2 2 300 210 0 0 4 300 nil nil nil nil nil
17 A MUPPIDATI 42 FEMALE 42110 1 2 3 2 2 2 2 2 340 215 0 0 2 4 480 nil nil nil nil nil
18 A KASINADAN 50 MALE 33752 2 2 2 2 2 2 2 2 290 218 0 2 4 300 nil nil nil nil nil
19 A SHANMUAVADIVU 56 FEMALE 33753 2 2 2 2 2 2 2 2 290 200 0 0 4 260 nil nil nil nil nil
20 A ULAGARANI 49 FEMALE 38702 2 2 2 2 2 2 2 2 310 200 0 0 2 4 480 nil nil nil nil nil
MASTER CHART: GROUP 'A' ‐ BUPIVACAINE WITH 5µg DEXMEDETOMIDINE
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21 B RAMASWAMY 39 MALE 33499 1 2 2 2 2 2 2 2 210 310 0 2 2 4 480 YES nil nil nil nil
22 B MARIAMMAL 35 FEMALE 37928 2 2 2 2 2 2 2 2 200 320 0 0 2 4 440 nil nil nil nil nil
23 B LEKSHMI 50 FEMALE 39018 2 2 2 2 3 3 3 3 240 360 0 0 0 2 4 500 nil nil nil nil nil
24 B MARIAPPAN 40 MALE 38700 1 2 2 2 2 2 2 2 300 300 0 2 2 4 480 nil nil nil nil nil
25 B BHAGAVATHI 48 FEMALE 4408 1 2 2 2 2 2 2 2 340 340 0 2 2 4 480 nil nil nil nil nil
26 B SARASWATI 50 FEMALE 4431 2 2 2 2 2 2 2 2 360 360 0 0 2 4 440 nil YES nil nil nil
27 B ARULRAJ 48 MALE 34715 1 2 2 2 3 3 3 3 380 380 0 0 0 2 4 500 nil nil nil nil nil
28 B PANDIRAJAN 39 MALE 34623 1 2 2 2 2 2 2 2 360 360 0 0 2 4 440 YES nil nil nil nil
29 B KALAISELVI 46 FEMALE 5857 1 2 2 2 2 2 2 2 320 320 0 2 2 4 480 nil nil nil nil nil
30 B KAMARAJ 48 MALE 33295 1 2 2 2 2 2 2 2 310 310 0 0 2 4 440 nil nil nil nil nil
31 B AMIRTHARANI 45 FEMALE 41163 2 2 2 2 3 3 3 3 300 300 0 0 0 2 4 500 nil nil nil nil nil
32 B MUTHUKARUPPAN 54 MALE 33210 1 2 2 2 2 2 2 2 290 290 0 2 2 4 480 nil nil nil nil nil
33 B MURUGAN 55 MALE 31529 2 2 2 2 2 2 2 2 280 280 0 2 2 4 480 nil nil nil nil nil
34 B MANONMANI 42 FEMALE 42023 1 2 2 2 2 2 2 2 300 300 0 0 2 4 440 nil nil nil nil nil
35 B ABDUL KHASIM 51 MALE 32714 1 2 2 2 3 3 3 3 220 280 0 0 0 2 4 500 nil nil nil nil nil
36 B KUMAR 38 MALE 31240 1 2 2 2 2 2 2 2 240 300 0 0 2 4 440 nil nil nil nil nil
37 B SANTHOSAM 45 FEMALE 39003 1 2 2 2 2 2 2 2 190 270 0 2 2 4 480 nil nil nil nil nil
38 B KANMANI 49 FEMALE 36928 2 2 2 2 2 2 2 2 320 340 0 0 2 4 440 nil nil nil nil nil
39 B RAJAMANI 52 MALE 31285 1 2 2 2 3 3 3 3 300 300 0 0 0 2 4 500 nil nil nil nil nil
40 B PANDIAMMAL 46 FEMALE 5383 1 2 2 2 2 2 2 2 340 340 0 2 2 4 480 nil nil nil nil nil
ADVERSE EFFECTSSEDATION SCORE VAS SCORE
MASTER CHART: GROUP 'B' ‐ BUPIVACAINE WITH 10µg DEXMEDETOMIDINE
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41 C MUTHUMALAI 50 FEMALE 4401 2 2 3 3 3 3 3 3 360 360 0 0 2 2 4 650 YES nil nil nil nil
42 C PAVANASAM 33 MALE 51238 1 2 3 3 3 3 3 3 350 370 0 0 2 2 4 720 nil nil nil nil nil
43 C RAJAMMAL 45 FEMALE 56546 1 2 2 3 4 4 4 4 340 350 0 0 2 2 4 800 nil nil nil nil nil
44 C MARIAMMAL 45 FEMALE 55539 1 2 2 3 3 4 4 4 280 365 0 0 0 2 4 840 nil nil nil nil nil
45 C SUMSUDIN 49 MALE 47549 2 2 2 3 3 3 3 3 280 370 0 0 2 2 4 680 nil nil nil nil nil
46 C RAMACHANDRAN 19 MALE 50397 2 2 2 2 3 3 3 3 280 350 0 0 0 2 4 780 YES nil nil nil nil
47 C VELSAMY 43 MALE 53937 1 2 2 3 3 4 4 4 280 340 0 0 0 2 2 750 nil nil nil nil nil
48 C MARIYAL 42 FEMALE 41441 2 2 2 3 3 3 3 3 280 370 0 0 0 2 4 710 nil YES nil nil nil
49 C PERUMAL 48 MALE 39055 1 2 2 3 4 4 4 4 340 390 0 0 0 2 2 750 nil nil nil nil nil
50 C JOTHI 35 FEMALE 33509 1 2 3 3 4 4 4 4 340 395 0 0 0 2 2 800 nil nil nil nil nil
51 C ESAKI MUTHU 45 MALE 39669 1 2 2 3 3 3 3 3 300 340 0 0 2 4 600 nil nil nil nil nil
52 C MANI 49 MALE 39601 1 2 2 3 4 4 4 4 300 335 0 0 0 2 4 730 nil nil nil nil nil
53 C PITCHAMMAL 45 FEMALE 38118 2 2 2 3 3 4 4 4 360 360 0 0 0 2 4 730 YES nil nil nil nil
54 C LEKSHMIAMMAL 55 FEMALE 40195 2 2 2 3 3 3 3 3 380 360 0 0 0 2 2 800 nil YES nil nil nil
55 C CHELAPPAN 46 MALE 34201 1 2 3 3 3 3 3 3 400 340 0 0 2 2 4 650 nil nil nil nil nil
56 C SULAIMAN 40 MALE 324102 1 2 3 3 3 3 3 3 410 370 0 0 2 2 4 720 nil nil nil nil nil
57 C GANDHIMATHI 50 FEMALE 37142 1 2 2 3 4 4 4 4 380 376 0 0 2 2 4 800 nil nil nil nil nil
58 C MANIAMMAL 46 FEMALE 39140 2 2 2 3 3 4 4 4 360 380 0 0 0 2 4 840 nil nil nil nil nil
59 C MUTHIAH 49 MALE 30119 1 2 2 3 3 3 3 3 420 370 0 0 2 2 4 680 nil nil nil nil nil
60 C PALAMMAL 54 FEMALE 39141 2 2 2 3 3 3 3 390 360 0 0 0 2 4 780 nil nil nil nil nil
SEDATION SCORE VAS SCORE ADVERSE EFFECTS
MASTER CHART: GROUP 'C' ‐ BUPIVACAINE WITH 15µg DEXMEDETOMIDINE
